Chimeric proteins for treating skin inflammation
Chimeric proteins combining TNFR2 and CLR domains provide a potential cure for psoriasis by inhibiting TNFα and blocking aberrant immune activation, addressing the limitations of current treatments.
Patent Information
- Application Number
- JP2024525999
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-29
- Filing Date
- 2022-11-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for psoriasis and other inflammatory skin diseases provide only temporary relief and can cause severe side effects, failing to address the underlying disease and often leading to relapse.
Development of chimeric proteins comprising a TNF receptor (TNFR2) and a C-type lectin receptor (CLR) linked by a hinge-CH2-CH3 Fc domain, which can be administered as purified proteins or encoded by nucleic acids, to inhibit TNFα and block aberrant activation of immune cells, thereby reducing inflammation.
The chimeric proteins effectively inhibit TNFα and reduce inflammation by sequestering ligands, blocking aberrant immune responses, offering a potential cure for psoriasis and other inflammatory diseases with reduced side effects.
Smart Images

Figure 2024543025000001_ABST
Abstract
Description
[Technical Field]
[0001] The present disclosure relates to compositions and methods, including, inter alia, heterologous chimeric proteins, or nucleic acids encoding chimeric proteins, that find use in the treatment of inflammatory diseases of the integumentary system.
[0002] Priority This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 274,232, filed November 1, 2021, U.S. Provisional Application No. 63 / 320,628, filed March 16, 2022, U.S. Provisional Application No. 63 / 325,568, filed March 30, 2022, and U.S. Provisional Application No. 63 / 369,836, filed July 29, 2022, the contents of each of which are incorporated herein by reference in their entirety.
[0003] Sequence Listing This application contains a Sequence Listing that has been submitted via the Patent Center in XML format. The contents of the XML copy entitled "SHK-054PC_116981-5054_Sequence Listing", created on October 31, 2022, and having a size of 117,810 bytes, are hereby incorporated by reference in their entirety. [Background technology]
[0004] Psoriasis is an inflammatory skin disease characterized by red, itchy, and scaly patches on the skin. It affects 2-3% of people worldwide and is thought to be driven by immune pathways. Traditionally, psoriasis has been treated with topical corticosteroids (e.g., triamcinolone acetonide and clobetasol propionate), topical keratolytics (e.g., salicylic acid), topical vitamin D3 analogs (e.g., calcitriol), oral or topical retinoids (e.g., tazarotene and acitretin), systemic cytotoxic agents (e.g., methotrexate), and immunosuppressants (e.g., cyclosporine). Recently, targeted agents have been developed. These agents include TNFα antagonists such as anti-TNFα antibodies (e.g., infliximab and adalimumab) and etanercept (a fusion protein of the TNF receptor TNFR2 and the Fc domain); anti-IL-12B (anti-IL-12 and anti-IL-23) antibodies (e.g., ustekinumab); anti-IL-23 antibodies (e.g., guselkumab); and anti-IL-17 antibodies (e.g., secukinumab).
[0005] There is no cure for psoriasis because all of the aforementioned treatments only provide temporary relief of symptoms rather than treating the underlying disease. As a result, these treatments only provide symptomatic remission at best and usually result in relapse. In exchange for temporary symptom relief, these treatments can cause mild to severe side effects, ranging from skin inflammation to susceptibility to serious infections, including tuberculosis. Furthermore, these treatments provide temporary relief of symptoms rather than treating the underlying disease, such as psoriatic arthritis (PsA), plaque psoriasis, rheumatoid arthritis (RA), juvenile arthritis, ankylosing spondylitis, inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease. Therefore, new therapies and approaches are needed to treat psoriasis and other inflammatory diseases, including inflammatory skin and GI tract diseases. Summary of the Invention
[0006] Thus, in various aspects, the present disclosure provides compositions and methods useful for treating, inter alia, inflammatory conditions of the integumentary system, such as skin inflammation of the integumentary system, including psoriasis.
[0007] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains and optionally comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand.
[0008] In embodiments, the portion of TNFR2 comprises the extracellular domain of TNFR2, or a fragment thereof. In embodiments, the portion of TNFR2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57.
[0009] In various embodiments, the CLR is selected from C-type lectin domain-containing 7A (Clec7A), Langerin, dendritic cell-specific intercellular adhesion molecule 3-binding nonintegrin (DC-SIGN), and dendritic cell-associated C-type lectin 2 (Dectin-2).
[0010] In embodiments, the second domain comprises a portion of Clec7a. In embodiments, the portion of Clec7a comprises the extracellular domain of Clec7a, or a fragment thereof capable of binding to β-1,3-linked and / or β-1,6-linked glucans. In embodiments, the portion of Clec7a comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59. In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57; a portion of Clec7a comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 59; and a linker adjacent to the extracellular domain.
[0011] In embodiments, the second domain comprises a portion of Langerin. In embodiments, the portion of Langerin comprises the extracellular domain of Langerin or a fragment thereof capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or beta-glucans. In embodiments, the portion of Langerin comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61. In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57; a portion of ranglin comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 60 or SEQ ID NO: 61; and a linker adjacent to the extracellular domain.
[0012] In embodiments, the second domain comprises a portion of DC-SIGN. In embodiments, the portion of DC-SIGN comprises the extracellular domain of DC-SIGN, or a fragment thereof capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3). In embodiments, the portion of DC-SIGN comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63. In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57; a portion of DC-SIGN comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 62 or SEQ ID NO: 63; and a linker adjacent to the extracellular domain.
[0013] In various embodiments, the second domain comprises a portion of Dectin-2. In various embodiments, the portion of Dectin-2 comprises the extracellular domain of Dectin-2, or a fragment thereof capable of binding to α-mannan. In various embodiments, the portion of Dectin-2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:65. In various embodiments, the chimeric protein comprises: an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of Dectin-2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:65; and a linker adjacent to the extracellular domain.
[0014] In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In various embodiments, the linker further comprises one or more coupled linkers, wherein such coupled linkers are independently selected from SEQ ID NOs:4-50. In various embodiments, the linker comprises two or more coupled linkers, each coupled linker independently selected from SEQ ID NOs:4-50, wherein one coupled linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other coupled linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0015] In one aspect, the present disclosure provides an isolated polynucleotide encoding any of the chimeric proteins of the embodiments disclosed herein. In various embodiments, the polynucleotide is or comprises an mRNA, such as a modified mRNA (mmRNA). In various embodiments, the polynucleotide is or comprises an mmRNA. In various embodiments, the mmRNA comprises one or more nucleoside modifications. In various embodiments, the mmRNA further comprises a 5' cap and / or a polyA tail.
[0016] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and the chimeric protein of any of the embodiments disclosed herein, the isolated polynucleotide of any of the embodiments disclosed herein, the mmRNA of any of the embodiments disclosed herein, the vector of any of the embodiments disclosed herein, or the host cell of any of the embodiments disclosed herein. In various embodiments, the pharmaceutical composition comprises the mmRNA of any of the embodiments disclosed herein.
[0017] In one aspect, the present disclosure provides a method of treating or preventing inflammation of the integumentary system, the method comprising administering to a subject a nucleic acid, e.g., an mmRNA, of any of the embodiments disclosed herein.
[0018] In one aspect, the present disclosure provides a method of treating or preventing inflammation of the integumentary system, said method comprising administering to a subject a pharmaceutical composition of any of the embodiments disclosed herein.
[0019] In one aspect, the present disclosure provides a method of treating or preventing inflammation of the integumentary system, the method comprising administering to a subject an mmRNA encoding a chimeric protein of any of the embodiments disclosed herein.
[0020] In one aspect, the present disclosure provides a method of treating or preventing a condition caused by inflammation, in embodiments, the condition is selected from psoriasis, psoriatic arthritis (PsA), plaque psoriasis, rheumatoid arthritis (RA), juvenile arthritis, ankylosing spondylitis, inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease.
[0021] In embodiments, the inflammation is caused by or associated with a disease or disorder of the integumentary system. In embodiments, the inflammation is caused by or associated with a skin disease or disorder. In embodiments, the skin disease or disorder is psoriasis, pemphigus vulgaris, scleroderma, atopic dermatitis, sarcoidosis, erythema nodosum, hidradenitis suppurativa, lichen planus, Sweet's syndrome, vitiligo, chronic paronychia, eczema, seborrheic dermatitis, and / or urticaria. In embodiments, the skin disease or disorder is psoriasis. In embodiments, the psoriasis is psoriasis vulgaris and / or psoriatic arthritis.
[0022] Any aspect or embodiment described herein may be combined with any other aspect or embodiment disclosed herein. [Brief explanation of the drawings]
[0023] [Figure 1A] 1 shows a schematic diagram of the type I transmembrane protein TNF receptor (TNFR2) (protein on the left) which has an extracellular amino terminus and an intracellular carboxy terminus, and the type II transmembrane protein C-type lectin receptor (CLR) (protein on the right) disclosed herein which has an extracellular carboxy terminus and an intracellular amino terminus. [Figure 1B] 1 shows a diagram of some embodiments of a chimeric protein disclosed herein that includes portions (e.g., extracellular domains) of a TNF receptor (TNFR2) and a C-type lectin receptor (CLR), with a linker connecting the two. [Figure 1C] 1 shows a diagram of some embodiments of a chimeric protein disclosed herein that includes portions (e.g., extracellular domains) of a TNF receptor (TNFR2) and a C-type lectin receptor (CLR), with a linker connecting the two. [Figure 1D] 1 shows a diagram of some embodiments of a chimeric protein disclosed herein that includes portions (e.g., extracellular domains) of two C-type lectin receptors (CLRs), with a linker connecting the two. [Figure 1E] 1 shows a diagram of some embodiments of a chimeric protein disclosed herein that includes portions (e.g., extracellular domains) of two C-type lectin receptors (CLRs), with a linker connecting the two. [Figure 2]Figures A-E show the construction of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. A shows a molecular weight ladder. B shows a Western blot of the TNFR2-Fc-Clec7a chimeric protein probed with anti-TNFR2, anti-Fc, and anti-Clec7a antibodies, demonstrating the presence of all three moieties in the chimeric protein. C shows a Western blot of the TNFR2-Fc-Dectin 2 chimeric protein probed with anti-TNFR2, anti-Fc, and anti-Dectin 2 antibodies, demonstrating the presence of all three moieties in the chimeric protein. D shows a Western blot of the TNFR2-Fc-DC-SIGN chimeric protein probed with anti-TNFR2, anti-Fc, and anti-DC-SIGN antibodies, demonstrating the presence of all three moieties in the chimeric protein. E is a Western blot of the TNFR2-Fc-Langerin chimeric protein probed with anti-TNFR2, anti-Fc, and anti-Langerin antibodies, demonstrating the presence of all three moieties in the chimeric protein. [Figure 3A]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3B]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3C]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3D]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3E]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3F]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 3G]Figures A–G show binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of human TNFR2-Fc-Clec7a chimeric protein to anti-human Clec7a antibody and anti-Fc antibody. Figure D shows simultaneous binding of human TNFR2-Fc-DC-SIGN chimeric protein to anti-human DC-SIGN antibody and anti-Fc antibody. Human DC-SIGN-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. Figure E shows simultaneous binding of human TNFR2-Fc-Dectin-2 chimeric protein to anti-human Dectin-2 antibody and anti-Fc antibody. An unrelated protein lacking human Dectin-2 was used as a negative control. Figure F shows simultaneous binding of human TNFR2-Fc-Langerin chimeric protein to anti-human Langerin antibody and anti-Fc antibody. Human Langerin-Fc protein and human TNFR2-Fc protein were used as positive and negative controls, respectively. G shows simultaneous binding to laminarin and anti-Fc antibody by human TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins. [Figure 4A]Figures A–D show the construction of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Figure A shows a Western blot characterizing the mouse TNFR2-Fc-Clec7 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Clec7 antibody (right blot). Figure B shows a Western blot characterizing the mouse TNFR2-Fc-Dectin 2 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Dectin 2 antibody (right blot). Figure C shows a Western blot characterizing the mouse TNFR2-Fc-DC-SIGN chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-DC-SIGN antibody (right blot). D is a Western blot showing the characterization of mouse TNFR2-Fc-Langerin chimeric proteins probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Langerin antibody (right blot). The Western blots demonstrate the native and multimer-forming tendencies of the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Untreated samples of the chimeric proteins (i.e., boiled without reducing or deglycosylating agents) were loaded in lane 1 of all blots. The sample in lane 2 was treated with the reducing agent β-mercaptoethanol and boiled. The sample in lane 3 was treated with the deglycosylating agent, reducing agent, and boiled. A protein size ladder was included in each blot. A shift in migration in lane 2 compared to lane 1 of each blot indicates oligomerization, and a shift in migration in lane 3 compared to lane 2 of each blot indicates glycosylation. [Figure 4B]Figures A–D show the construction of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Figure A shows a Western blot characterizing the mouse TNFR2-Fc-Clec7 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Clec7 antibody (right blot). Figure B shows a Western blot characterizing the mouse TNFR2-Fc-Dectin 2 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Dectin 2 antibody (right blot). Figure C shows a Western blot characterizing the mouse TNFR2-Fc-DC-SIGN chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-DC-SIGN antibody (right blot). D is a Western blot showing the characterization of mouse TNFR2-Fc-Langerin chimeric proteins probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Langerin antibody (right blot). The Western blots demonstrate the native and multimer-forming tendencies of the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Untreated samples of the chimeric proteins (i.e., boiled without reducing or deglycosylating agents) were loaded in lane 1 of all blots. The sample in lane 2 was treated with the reducing agent β-mercaptoethanol and boiled. The sample in lane 3 was treated with the deglycosylating agent, reducing agent, and boiled. A protein size ladder was included in each blot. A shift in migration in lane 2 compared to lane 1 of each blot indicates oligomerization, and a shift in migration in lane 3 compared to lane 2 of each blot indicates glycosylation. [Figure 4C]Figures A–D show the construction of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Figure A shows a Western blot characterizing the mouse TNFR2-Fc-Clec7 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Clec7 antibody (right blot). Figure B shows a Western blot characterizing the mouse TNFR2-Fc-Dectin 2 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Dectin 2 antibody (right blot). Figure C shows a Western blot characterizing the mouse TNFR2-Fc-DC-SIGN chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-DC-SIGN antibody (right blot). D is a Western blot showing the characterization of mouse TNFR2-Fc-Langerin chimeric proteins probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Langerin antibody (right blot). The Western blots demonstrate the native and multimer-forming tendencies of the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Untreated samples of the chimeric proteins (i.e., boiled without reducing or deglycosylating agents) were loaded in lane 1 of all blots. The sample in lane 2 was treated with the reducing agent β-mercaptoethanol and boiled. The sample in lane 3 was treated with the deglycosylating agent, reducing agent, and boiled. A protein size ladder was included in each blot. A shift in migration in lane 2 compared to lane 1 of each blot indicates oligomerization, and a shift in migration in lane 3 compared to lane 2 of each blot indicates glycosylation. [Figure 4D]Figures A–D show the construction of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Figure A shows a Western blot characterizing the mouse TNFR2-Fc-Clec7 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Clec7 antibody (right blot). Figure B shows a Western blot characterizing the mouse TNFR2-Fc-Dectin 2 chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Dectin 2 antibody (right blot). Figure C shows a Western blot characterizing the mouse TNFR2-Fc-DC-SIGN chimeric protein probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-DC-SIGN antibody (right blot). D is a Western blot showing the characterization of mouse TNFR2-Fc-Langerin chimeric proteins probed with anti-TNFR2 antibody (left blot), anti-Fc antibody (middle blot), and anti-Langerin antibody (right blot). The Western blots demonstrate the native and multimer-forming tendencies of the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Untreated samples of the chimeric proteins (i.e., boiled without reducing or deglycosylating agents) were loaded in lane 1 of all blots. The sample in lane 2 was treated with the reducing agent β-mercaptoethanol and boiled. The sample in lane 3 was treated with the deglycosylating agent, reducing agent, and boiled. A protein size ladder was included in each blot. A shift in migration in lane 2 compared to lane 1 of each blot indicates oligomerization, and a shift in migration in lane 3 compared to lane 2 of each blot indicates glycosylation. [Figure 5A]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5B]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5C]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5D]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5E]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5F]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5G]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5H]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5I]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5J]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5K]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5L]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5M]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 5N]Figures A–N show binding of mouse TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to their respective ligands, as measured using a Meso Scale Discovery (MSD) platform-based ELISA assay. Figure A shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to anti-TNFR and anti-Fc antibodies. Figure B shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, and TNFR2-Fc-Langerin chimeric proteins to TNFα and anti-Fc antibodies. Figure C shows simultaneous binding of TNFR2-Fc-Clec7a chimeric proteins to anti-Clec7a and anti-Fc antibodies. D shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-DC-SIGN chimeric protein. E shows simultaneous binding of anti-DC-SIGN and anti-Fc antibodies by the TNFR2-Fc-Dectin 2 chimeric protein. F shows simultaneous binding of anti-Langerin and anti-Fc antibodies by the TNFR2-Fc-Langerin chimeric protein. G shows simultaneous binding of laminarin and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. H shows simultaneous binding of galectin-9 and anti-Fc antibodies by the TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins. Panel I shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to dextran sulfate sodium salt (DSS) and anti-Fc antibody. Panel J shows simultaneous binding of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin 2, and TNFR2-Fc-Langerin chimeric proteins to zymosan and anti-Fc antibody.K shows simultaneous binding of inter-alpha inhibitor heavy chain 4 (ITIH4) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. L shows simultaneous binding of hyaluronic acid binding protein 1 (HABP1) and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. M shows simultaneous binding of CAECAM1 and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. N shows simultaneous binding of BTN2A1-His and anti-Fc antibody by the TNFR2-Fc-DC-SIGN chimeric protein. [Figure 6] 1 shows the detection of mRNA encoding intracellular TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins using qPCR 24 hours after transfection into CHOK1 cells. [Figure 7A] A–C show the expression of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins measured using a Meso Scale Discovery (MSD) platform-based ELISA assay 24 hours after transfection of L929 (A), HEK293 (B), or CHOK1 cells (C) with mRNA encoding the chimeric proteins. [Figure 7B] A–C show the expression of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins measured using a Meso Scale Discovery (MSD) platform-based ELISA assay 24 hours after transfection of L929 (A), HEK293 (B), or CHOK1 cells (C) with mRNA encoding the chimeric proteins. [Figure 7C]A–C show the expression of TNFR2-Fc-Clec7a, TNFR2-Fc-DC-SIGN, TNFR2-Fc-Dectin2, and TNFR2-Fc-Langerin chimeric proteins measured using a Meso Scale Discovery (MSD) platform-based ELISA assay 24 hours after transfection of L929 (A), HEK293 (B), or CHOK1 cells (C) with mRNA encoding the chimeric proteins. [Figure 8A] Figures A and B show that the chimeric proteins disclosed herein sequester ligand and block reporter cell activation. Figure A shows activation of the secreted alkaline phosphatase (SEAP) reporter in HEK-Blue® Dectin-2 cells incubated with TNFα in the presence of TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin-2 chimeric proteins, or an unrelated protein used as a negative control. Figure B shows activation of the secreted alkaline phosphatase (SEAP) reporter in HEK-Blue® Dectin-1b cells incubated with glycan / carbohydrate zymosan in the presence of buffer alone, TNFR2-Fc-Clec7a chimeric protein, or a negative control chimeric protein. [Figure 8B] Figures A and B show that the chimeric proteins disclosed herein sequester ligand and block reporter cell activation. Figure A shows activation of the secreted alkaline phosphatase (SEAP) reporter in HEK-Blue® Dectin-2 cells incubated with TNFα in the presence of TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin-2 chimeric proteins, or an unrelated protein used as a negative control. Figure B shows activation of the secreted alkaline phosphatase (SEAP) reporter in HEK-Blue® Dectin-1b cells incubated with glycan / carbohydrate zymosan in the presence of buffer alone, TNFR2-Fc-Clec7a chimeric protein, or a negative control chimeric protein. [Figure 9A]Figures A and B show that the chimeric proteins disclosed herein inhibit TNFα-induced apoptosis in L929 fibroblasts. Figure A shows the inhibition of apoptosis by mmRNA encoding the chimeric proteins disclosed herein. L929 fibroblasts were transfected with empty LNPs or LNPs containing mmRNA encoding TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin 2 chimeric proteins, or an unrelated chimeric protein, and then treated with increasing amounts of TNFα. The extent of apoptosis, as measured by cleaved caspase 3 / 7 activity, was plotted as a function of the amount of TNFα. Figure B shows the inhibition of apoptosis by the chimeric proteins disclosed herein. L929 fibroblasts were incubated with TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin 2 chimeric proteins, or an unrelated chimeric protein, in the presence of increasing amounts of TNFα. The degree of apoptosis, as measured by cleaved caspase 3 / 7 activity, was plotted as a function of the chimeric protein:TNFα molar ratio. An irrelevant chimeric protein was used as a negative control. [Figure 9B]Figures A and B show that the chimeric proteins disclosed herein inhibit TNFα-induced apoptosis in L929 fibroblasts. Figure A shows the inhibition of apoptosis by mmRNA encoding the chimeric proteins disclosed herein. L929 fibroblasts were transfected with empty LNPs or LNPs containing mmRNA encoding TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin 2 chimeric proteins, or an unrelated chimeric protein, and then treated with increasing amounts of TNFα. The extent of apoptosis, as measured by cleaved caspase 3 / 7 activity, was plotted as a function of the amount of TNFα. Figure B shows the inhibition of apoptosis by the chimeric proteins disclosed herein. L929 fibroblasts were incubated with TNFR2-Fc-Clec7a or TNFR2-Fc-Dectin 2 chimeric proteins, or an unrelated chimeric protein, in the presence of increasing amounts of TNFα. The degree of apoptosis, as measured by cleaved caspase 3 / 7 activity, was plotted as a function of the chimeric protein:TNFα molar ratio. An irrelevant chimeric protein was used as a negative control. [Figure 10A] Figures A and B show the in vivo therapeutic activity of the chimeric proteins disclosed herein in a mouse colitis model. Figure A is a bar graph showing the change in body weight on day 8. Figure B is a bar graph showing the percentage of CD3CD45CD4 and CD3CD45CD8 cells among total CD4 / CD8 cells. [Figure 10B] Figures A and B show the in vivo therapeutic activity of the chimeric proteins disclosed herein in a mouse colitis model. Figure A is a bar graph showing the change in body weight on day 8. Figure B is a bar graph showing the percentage of CD3CD45CD4 and CD3CD45CD8 cells among total CD4 / CD8 cells. DETAILED DESCRIPTION OF THE INVENTION
[0024] Disclosed herein are dual-acting chimeric proteins and nucleic acids encoding the chimeric proteins that, for example, (1) disrupt, block, reduce, and / or inhibit the activity of TNFα, a cytokine that causes tissue inflammation, by, for example, but not limited to, sequestering TNFα and / or inhibiting the function of cellular TNF receptor species, and (2) disrupt, block, reduce, and / or inhibit the transduction of pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern (DAMP, alarmin) cellular hyperactivity / abnormal sensing (e.g., by sequestering ligands that activate PAMPs / DAMP receptors), thereby preventing hyperactivation / abnormal activation of macrophages, monocytes, and / or dendritic cells. Thus, without being bound by theory, the chimeric proteins disclosed herein or nucleic acids encoding them provide anti-inflammatory and / or anti-autoimmune effects through two distinct pathways. This dual action likely provides a therapeutic benefit to patients and / or likely provides an enhanced therapeutic benefit to patients. Furthermore, without being bound by theory, it is believed that such chimeric proteins, because they can act through two different pathways, may be effective, at least in patients who are poor responders to therapies that target one of the two pathways. Thus, patients who are poor responders to therapies that act through one of the two pathways may achieve therapeutic benefit by targeting the other pathway.
[0025] Disclosed herein are chimeric proteins, and nucleic acids encoding same, that comprise a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, linked via a linker to a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand (such as, but not limited to, Clec7A, Langerin, DC-SIGN, and Dectin-2).
[0026] The first and second domains are present on the same polypeptide; therefore, (1) the chimeric proteins disclosed herein are produced by a single transcript, and (2) unlike antibodies, heterodimerization of the two polypeptides is not required. Therefore, the chimeric proteins disclosed herein can be delivered as purified proteins or as nucleic acids encoding the chimeric proteins disclosed herein. Thus, the present disclosure is also based, in part, on the delivery of nucleic acids encoding the chimeric proteins, for example, to the skin. Isolated polynucleotides encoding the chimeric proteins disclosed herein and / or the chimeric proteins disclosed herein can be used to treat diseases or disorders caused by or associated with inflammation of the integumentary system. Isolated polynucleotides encoding the chimeric proteins disclosed herein and / or the chimeric proteins disclosed herein can be delivered by any administration method suitable for treating the integumentary system, for example, by topical administration.
[0027] Chimeric proteins of the present disclosure Transmembrane proteins typically consist of an extracellular domain, one or a series of transmembrane domains, and an intracellular domain. Without being bound by theory, the extracellular domain of a transmembrane protein is responsible for interacting with a soluble receptor or ligand or a membrane-bound receptor or ligand (i.e., the membrane of an adjacent cell). Without being bound by theory, the transmembrane domain(s) localize the transmembrane protein to the plasma membrane. Without being bound by theory, the intracellular domain of a transmembrane protein coordinates interactions with intracellular signaling molecules and coordinates intracellular responses with the extracellular environment (or vice versa). Thus, depending on the context, a transmembrane protein may function as a receptor (i.e., initiates signal transduction in response to stimulation by a cognate ligand), a ligand (i.e., stimulates signal transduction in cells with its cognate receptor), or both a receptor and a ligand (i.e., stimulates signal transduction response binding of a cognate ligand and initiates signal transduction in cells with its cognate receptor).
[0028] Single-pass transmembrane proteins are generally of two types: type I transmembrane proteins, which have an extracellular amino terminus and an intracellular carboxy terminus, and type II transmembrane proteins, which have an extracellular carboxy terminus and an intracellular amino terminus (see FIG. 1A, right protein). The TNF receptor (TNFR2) has an extracellular amino terminus and an intracellular carboxy terminus and is a type I transmembrane protein (see FIG. 1A, left protein). The C-type lectin receptors (CLRs) disclosed herein have an extracellular carboxy terminus and an intracellular amino terminus and are type II transmembrane proteins. For type I transmembrane proteins (e.g., TNFR2), the amino terminus of the protein faces the outside of the cell and thus contains the functional domain involved in interaction with other binding partners (either ligands or receptors, e.g., TNFα) in the extracellular environment. For type II transmembrane proteins (e.g., the C-type lectin receptors (CLRs) disclosed herein), the carboxy terminus of the protein faces the outside of the cell and thus contains the functional domain involved in interaction with other binding partners (either ligands or receptors) in the extracellular environment. Thus, these two types of transmembrane proteins have opposite orientations relative to the plasma membrane, with the amino termini of type I transmembrane proteins pointing away from the membrane, and the amino termini of type II transmembrane proteins pointing towards the membrane.
[0029] In embodiments, an extracellular domain refers to a portion of a transmembrane protein that can interact with the extracellular environment. In embodiments, an extracellular domain refers to a portion of a transmembrane protein that is sufficient to bind a ligand or receptor and is effective to transmit a signal to the cell. In embodiments, an extracellular domain is typically the entire amino acid sequence of a transmembrane protein that resides outside a cell or cell membrane. In embodiments, an extracellular domain is a portion of the amino acid sequence of a transmembrane protein that is outside a cell or cell membrane and required for signaling and / or ligand binding, as may be assayed using methods known in the art (e.g., in vitro ligand binding and / or cell activation assays).
[0030] In some aspects, chimeric proteins of the present disclosure include a type I transmembrane protein (e.g., TNFR2) and a type II transmembrane protein (e.g., a C-type lectin receptor (CLR) disclosed herein), which can be engineered such that their transmembrane and intracellular domains are removed and the extracellular domains of the transmembrane proteins are adjacent using a linker sequence to generate a single chimeric protein. In various embodiments, as shown in Figures 1B and 1C, the extracellular domain of TNFR2 (a type I transmembrane protein) and the extracellular domain of a C-type lectin receptor (CLR) disclosed herein (a type II transmembrane protein) are combined into a single chimeric protein. Figure 1B illustrates some embodiments in which the linkage between free TNFR2 (a type I transmembrane protein freed from the transmembrane and intracellular domains) or free carboxy-terminal anchored extracellular protein (from the anchor domain) and free C-type lectin receptor (CLR) disclosed herein (a type II transmembrane protein freed from the transmembrane and intracellular domains) is adjacent by a linker sequence. The extracellular domain in this figure includes the entire amino acid sequence of the extracellular domain of TNFR2, or a portion thereof, which retains the ability to bind to TNFα. Similarly, the extracellular domain in this figure includes the entire amino acid sequence of a C-type lectin receptor (CLR) disclosed herein, or a portion thereof, which retains the ability to bind to its intended ligand / receptor. Furthermore, the chimeric proteins of these embodiments include sufficient overall flexibility and / or physical distance between the domains such that the first extracellular domain (shown at the left end of the chimeric protein in Figures 1B and 1C) can sterically bind to its receptor / ligand and / or the second extracellular domain (shown at the right end of the chimeric protein in Figures 1B and 1C) can sterically bind to its receptor / ligand. Figure 1C shows adjacent extracellular domains in a linear chimeric protein, with each extracellular domain of the chimeric protein facing "outward."
[0031] In some aspects, a chimeric protein of the present disclosure comprises the extracellular domains of two C-type lectin receptors (CLRs) (type II transmembrane proteins) disclosed herein, e.g., extracellular domains from two different C-type lectin receptors (CLRs) or two extracellular domains from a single C-type lectin receptor. Thus, the chimeric protein of these embodiments comprises at least a first domain comprising the extracellular domain of a first C-type lectin receptor (CLR), connected—either directly or via a linker—to a second domain comprising the extracellular domain of a second C-type lectin receptor (CLR). When the domains are linked in an amino- to carboxy-terminal orientation, as shown in Figures 1D and 1E, the first domain is located on the "left" of the chimeric protein and faces "inward," and the second domain is located on the "right" of the chimeric protein and faces "outward."
[0032] Other configurations of the first and second domains are envisioned, for example, the first domain facing outward and the second domain facing inward, the first and second domains both facing inward, and the first and second domains both facing outward.
[0033] The chimeric proteins of the present invention and nucleic acids encoding the chimeric proteins of the present invention offer advantages, including, but not limited to, ease of use and ease of production. This is because two different immunotherapeutic agents may be combined into one product, allowing for a single manufacturing process instead of two separate manufacturing processes. Furthermore, administering one drug instead of two separate drugs facilitates administration and improves patient compliance. Furthermore, in contrast to, for example, monoclonal antibodies, which are large, multimeric proteins containing numerous disulfide bonds and post-translational modifications such as glycosylation, the chimeric proteins of the present invention and nucleic acids encoding the chimeric proteins of the present invention are easy to manufacture and cost-effective to produce. Furthermore, in contrast to, for example, monoclonal antibodies, which are generated from two polypeptide chains that must be biosynthesized from nucleic acids, possibly using at least two open reading frames, nucleic acids encoding the chimeric proteins of the present invention comprise a single polypeptide biosynthesized from a single nucleic acid molecule bearing a single open reading frame encoding the chimeric proteins of the present invention. Therefore, the chimeric proteins of the present invention may be suitably administered as purified chimeric proteins or as nucleic acids encoding the chimeric proteins.
[0034] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains and optionally comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand.
[0035] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the same, wherein the chimeric protein comprises a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, optionally adjacent to a second domain comprising a portion of a C-type lectin receptor (CLR) via a linker comprising a hinge-CH2-CH3 Fc domain. In various embodiments, the portion of TNFR2 comprises the extracellular domain of TNFR2 or a fragment thereof capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor.
[0036] TNFR2 is a single-spanning type I transmembrane protein characterized by having four cysteine-rich domains (CRDs) in its extracellular domain. In various embodiments, the extracellular domain of TNFR2, or a fragment thereof, inhibits TNFα by competing with cellular receptor species for TNF binding through sequestration. In various embodiments, the first domain inhibits TNFα by oligomerizing with cellular TNF receptor species to form an inactive complex, thereby inhibiting the function of the cellular TNF receptor species.
[0037] In embodiments, the first domain comprises the extracellular domain of TNFR2 having the following sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGD (SEQ ID NO: 57).
[0038] In various embodiments, the chimeric protein comprises a variant of the extracellular domain of TNFR2. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0039] In embodiments, the portion of TNFR2 comprises the extracellular domain of TNFR2, or a fragment thereof. In embodiments, the portion of TNFR2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57.
[0040] One skilled in the art would refer to the literature and structural information, such as Kohno et al., “A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.” Proc. Natl. Acad. Sci. U.S.A. 87(21), 8331 - 8335 (1990); Smith et al., “A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.” Science 248(4958), 1019 - 1023 (1990); Loetscher et al., “Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.” J. Biol. Chem. 265(33), 20131 - 20138 (1990); Dembic, et al., “Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences.” Cytokine 2(4), 231 - 237 (1990); Pennica et al., “Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation.” J. Biol. Chem. 267(29), 21172 - 21178 (1992); and Park et al., “Structural basis for self-association and receptor recognition of human TRAF2." Nature 398(6727), 533-538(1999); Mukai et al., "Solution of the structure of the TNF-TNFR2 complex." Sci Signal. 3(148):ra83(2010); TNF-TNFR2 structure PDB ID: 3ALQ (each of which is incorporated by reference in its entirety) can be used to select variants of the known amino acid sequence of TNFR2.
[0041] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the same, comprising a first domain comprising a portion of a tumor necrosis factor receptor (TNFR2), optionally flanked by a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand via a linker comprising a hinge-CH2-CH3 Fc domain. In embodiments, the ligand is a natural ligand of the CLR. In embodiments, the CLR is selected from C-type lectin domain-containing 7A (Clec7A), langerin, dendritic cell-specific intercellular adhesion molecule 3-binding nonintegrin (DC-SIGN), and dendritic cell-associated C-type lectin 2 (Dectin-2).
[0042] In embodiments, the second domain inhibits aberrant and / or excessive activation of macrophages by blocking aberrant sensing of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs, alarmins). In embodiments, ligands for C-type lectin receptors (CLRs) are PAMPs and / or DAMPs. In embodiments, the second domain inhibits, reduces, or blocks the initial recognition and uptake of PAMPs and / or DAMPs. In embodiments, the second domain inhibits, reduces, or blocks the macrophage-mediated inflammatory cascade initiated by the initial recognition and uptake of PAMPs and / or DAMPs.
[0043] In various embodiments, the second domain inhibits, blocks or reduces the initiation of an inflammatory response initiated by macrophages, monocytes and / or dendritic cells upon aberrant sensing of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs, alarmins), thereby blocking, reducing and / or inhibiting the production of pro-inflammatory cytokines such as TNFα, IL-17 and IL-23 by macrophages, monocytes and / or dendritic cells.
[0044] In embodiments, the second domain comprises a portion of Clec7a (also known as dendritic cell-associated C-type lectin-1 (Dectin-1) or CD369). In embodiments, the portion of Clec7a comprises the extracellular domain of Clec7a, or a fragment thereof capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
[0045] Clec7a is a transmembrane protein that contains a C-type lectin binding domain (CLD, also called carbohydrate recognition domain, CRD) in its extracellular region, which recognizes β-1,3-linked and / or β-1,6-linked glucans on T cells as well as endogenous ligands. In various embodiments, the second domain comprises a CLD.
[0046] In embodiments, the second domain comprises the extracellular domain (ECD) of Clec7a, which has the following sequence: TMAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTTGVLSSPCPPNWIIYEKSCYLFSMSLNSWDGSKRQCWQLGSNLLKIDSSNELGFIVKQVSSQPDNSFWIGLSRPQTEVPWLWEDGSTFSSNLFQIRTTATQENPSPNCVWIHVSVIYDQLCSVPSYSICEKKFSM (SEQ ID NO: 58).
[0047] In various embodiments, the chimeric protein comprises a variant of the extracellular domain (ECD) of Clec7a. By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0048] In embodiments, the second domain comprises the C-type lectin binding domain (CLD) of Clec7a, having the following sequence: SSPCPPNWIIYEKSCYLFSMSLNSWDGSKRQCWQLGSNLLKIDSSNELGFIVKQVSSQPDNSFWIGLSRPQTEVPWLWEDGSTFSSNLFQIRTTATQENPSPNCVWIHVSVIYDQLCSVPSYSICEKKFSM (SEQ ID NO: 59)
[0049] In various embodiments, the chimeric protein comprises a variant of the C-type lectin binding domain (CLD) of Clec7a. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0050] In embodiments, the portion of Clec7a comprises the extracellular domain of Clec7a, or a fragment thereof. In embodiments, the portion of Clec7a comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59. In embodiments, the first domain of the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59.
[0051] Those skilled in the art can select variants of the known amino acid sequence of Clec7a by referring to literature and structural information, for example, Brown et al., Structure of the Fungal Beta-Glucan-Binding Immune Receptor Dectin-1: Implications for Protein Sci 16:1042-1052 (2007); TNF-TNFR2 structure PDB ID: 2BPE; Alphafold structure (Jumper et al., Highly accurate protein structure prediction with AlphaFold. Nature 596:583-589 (2021)); Legentil et al., Molecular Interactions of β-(1→3)-Glucans with Their Receptors, Molecules 20(6):9745-66 (2015) (each of which is incorporated by reference in its entirety).
[0052] In embodiments, the second domain comprises a portion of Langerin (also known as C-type lectin domain family 4 member K or CD207). In embodiments, the portion of Langerin comprises the extracellular domain of Langerin, or a fragment thereof capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or beta-glucans.
[0053] Langerin is a calcium-dependent lectin that exhibits mannose-binding specificity. It promotes antigen uptake and is involved in routing and / or processing of antigens for presentation to T cells. Langerin is the primary receptor for primary Langerhans cells of Candida, Saccharomyces, and Malassezia species. It binds to the high-mannose structures present in the HIV viral envelope glycoprotein, subsequently targeting the virus to Birbeck granules for rapid degradation.
[0054] In embodiments, the second domain comprises the extracellular domain (ECD) of Langerin, which has the following sequence: PRFMGTISDVKTNVQLLKGRVDNISTLDSEIKKNSDGMEAAGVQIQMVNESLGYVRSQFLKLKTSVEKANAQIQILTRSWEEVSTLNAQIPELKSDLEKASALNTKIRALQGSLENMSKLLKRQNDILQVVSQGWKYFKGNFYYFSLIPKTWYSAEQFCVSRNSHLTSVTSESEQEFLYKTAGGLIYWIGLTKAGMEGDWSWVDDTPFNKVQSVRFWIPGEPNNAGNNEHCGNIKAPSLQAWNDAPCDKTFLFICKRPYVPSEP (SEQ ID NO: 60).
[0055] In various embodiments, the chimeric protein comprises a variant of the extracellular domain of Langerin. By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0056] In embodiments, the second domain comprises the C-type lectin binding domain (CLD) of Langerin, which has the following sequence: QVVSQGWKYFKGNFYYFSLIPKTWYSAEQFCVSRNSHLTSVTSESEQEFLYKTAGGLIYWIGLTKAGMEGDWSWVDDTPFNKVQSVRFWIPGEPNNAGNNEHCGNIKAPSLQAWNDAPCDKTFLFICKRPYVPSEP (SEQ ID NO: 61)
[0057] In various embodiments, the chimeric protein comprises a variant of the C-type lectin binding domain (CLD) of Langerin. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0058] In embodiments, the portion of Langerin comprises the extracellular domain of Langerin, or a fragment thereof. In embodiments, the portion of Langerin comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61. In embodiments, the first domain of the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61.
[0059] A person skilled in the art would be aware of the literature and structural information, such as Nurisso et al., Structural studies of langerin and Birbeck granule: a macromolecular organization model, Biochemistry 48:2684 - 98 (2009); Feinberg et al., Trimeric structure of langerin. J. Biol. Chem. 285:13285 - 93 (2010); Feinberg et al., Structural basis for langerin recognition of diverse pathogen and mammalian glycans through a single binding site. J. Mol. Biol. 405:1027 - 39 (2011); Chatwell et al., The carbohydrate recognition domain of langerin reveals high structural similarity with the one of DC - SIGN but an additional, calcium - independent sugar - binding site, Mol. Immunol. 45:1981 - 94 (2008); Chabrol et al., Alteration of the langerin oligomerization state affects birbeck granule formation, Biophys. J. 108:666 - 77 (2015); Feinberg et al., Common polymorphisms in human langerin change specificity for glycan ligands. J. Biol. Chem. 288(52):36762 - 36771(2013); Porkolab et al., Rational - Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC - SIGN and Excluding Langerin Recognition.Variants of the known amino acid sequence of Langerin can be selected by referring to ACS Chem. Biol. 13(3):600-608 (2018); Alphafold structure (Jumper et al., Highly accurate protein structure prediction with AlphaFold. Nature 596:583-589 (2021)), each of which is incorporated herein by reference in its entirety.
[0060] In embodiments, the second domain comprises a portion of DC-SIGN (also known as C-type lectin domain family 4 member L or CD209). In embodiments, the portion of DC-SIGN comprises the extracellular domain of DC-SIGN, or a fragment thereof capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
[0061] DC-SIGN is a pathogen recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in the initiation of primary immune responses. It is thought to mediate the endocytosis of pathogens, followed by their degradation in the lysosomal compartment.
[0062] In embodiments, the second domain comprises the extracellular domain of DC-SIGN, which has the following sequence: QVSKVPSSISQEQSRQDAIYQNLTQLKAAVGELSEKSKLQEIYQELTQLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTWLKAAVGELPEKSKMQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTQLKAAVERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKCNLAKFWICKKSAASCSRDEEQFLSPAPATPNPPPA (SEQ ID NO: 62).
[0063] In various embodiments, the chimeric protein comprises a variant of the extracellular domain (ECD) of DC-SIGN. By way of example, the variant has a similar affinity to SEQ ID NO: 62, at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0064] In embodiments, the second domain comprises the C-type lectin binding domain (CLD) of DC-SIGN, which has the following sequence: HPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKCNLAKFWICK (SEQ ID NO: 63)
[0065] In various embodiments, the chimeric protein comprises a variant of the C-type lectin binding domain (CLD) of DC-SIGN. By way of example, the variant has a similar affinity to SEQ ID NO: 63, at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0066] In embodiments, the portion of DC-SIGN comprises the extracellular domain of DC-SIGN, or a fragment thereof. In embodiments, the portion of DC-SIGN comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63. In embodiments, the first domain of the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63.
[0067] A person skilled in the art would be familiar with the literature and structural information, such as Feinberg et al., Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR, Science 294:2163-6 (2001); Guo et al., Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR, Nat. Struct. Mol. Biol. 11:591-8 (2004); Pokidysheva et al., Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN, Cell 124:485-93 (2006); Feinberg et al., Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J. Biol. Chem. 282 4202-9 (2007); Thepaut et al., Structure of a glycomimetic ligand in the carbohydrate recognition domain of C-type lectin DC-SIGN. Structural requirements for selectivity and ligand design. J. Am. Chem. Soc. 135 2518-29 (2013); Medve et al., Enhancing potency and selectivity of a DC-SIGN glycomimetic ligand by fragment-based design: structural basis. Chemistry 25(64):14659-14668 (2019); Sutkeviciute et al.Variants of the known amino acid sequence of DC-SIGN can be selected by referring to: Unique DC-SIGN Clustering Activity of a Small Glycomimetic: A Lesson for Ligand Design. ACS Chem. Biol. 9(6):1377-1385(2014); Porkolab et al., Rational-Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC-SIGN and Excluding Langerin Recognition. ACS Chem. Biol. 13(3):600-608(2018); Alphafold structure (Jumper et al., Highly accurate protein structure prediction with AlphaFold. Nature 596:583-589(2021)) (each of which is incorporated herein by reference in its entirety).
[0068] In embodiments, the second domain comprises a portion of Dectin-2 (also known as C-type lectin domain family 6 member A or C-type lectin superfamily member 10). In embodiments, the portion of Dectin-2 comprises the extracellular domain of Dectin-2, or a fragment thereof capable of binding to α-mannan.
[0069] Dectin-2 is a calcium-dependent lectin that functions as a pattern recognition receptor (PRR) of the innate immune system and specifically recognizes and binds to α-mannan on C. albicans hyphae. In various embodiments, the portion of dectin-2 comprises the extracellular domain of dectin-2 or a fragment thereof that can recognize allergens from house dust mites and fungi in a mannose-dependent manner, and / or soluble elements from Schistosoma mansoni eggs that alter the adaptive immune response.
[0070] In embodiments, the second domain comprises the extracellular domain of Dectin-2 having the following sequence: TYHFTYGETGKRLSELHSYHSSLTCFSEGTKVPAWGCCPASWKSFGSSCYFISSEEKVWSKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQWIDKTPYEKNVRFWHLGEPNHSAEQCASIVFWKPTGWGWNDVICETRRNSICEMNKIYL (SEQ ID NO: 64).
[0071] In various embodiments, the chimeric protein comprises a variant of the extracellular domain of Dectin 2. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0072] In embodiments, the second domain comprises a C-type lectin binding domain (CLD) of Dectin-2 having the following sequence: FGSSCYFISSEEKVWSKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQWIDKTPYEKNVRFWHLGEPNHSAEQCASIVFWKPTGWGWNDVICETRRNSICE (SEQ ID NO: 65)
[0073] In various embodiments, the chimeric protein comprises a variant of the C-type lectin binding domain (CLD) of Dectin 2. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0074] In embodiments, the portion of Dectin 2 comprises the extracellular domain of Dectin 2, or a fragment thereof. In embodiments, the portion of Dectin 2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 65. In embodiments, the first domain of the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 65.
[0075] Those skilled in the art will be familiar with the structure of Dectin-2 by reference to literature and structural information, for example, Feinberg et al., Mechanism of pathogen recognition by human dectin-2. J. Biol. Chem. 292(32):13402-13414(2017); Decout et al., Deciphering the molecular basis of mycobacteria and lipoglycan recognition by the C-type lectin Dectin-2, Scientific Reports 8:16840(2018); McGreal et al., The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose, Glycobiology, 16(5):422-430(2006); Alphafold structure (Jumper et al., Highly accurate protein structure prediction with AlphaFold. Variants of the known amino acid sequence of Dectin 2 can be selected by referring to Nature 596:583-589(2021) (each of which is incorporated herein by reference in its entirety).
[0076] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the same, wherein the chimeric protein comprises a first domain comprising a portion of a first C-type lectin receptor (CLR), optionally adjacent to a second domain comprising a portion of a second C-type lectin receptor (CLR) capable of binding to a ligand, via a linker comprising a hinge-CH2-CH3 Fc domain. In embodiments, the ligand is a natural ligand of the CLR. In embodiments, the first CLR and the second CLR are independently selected from C-type lectin domain-containing 7A (Clec7A), langerin, dendritic cell-specific intercellular adhesion molecule 3-binding nonintegrin (DC-SIGN), and dendritic cell-associated C-type lectin 2 (Dectin-2). In embodiments, the first CLR and the second CLR independently comprise an extracellular domain (ECD) or a C-type lectin-binding domain (CLD).
[0077] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a first C-type lectin receptor (CLR) capable of binding to its ligand, (b) is a linker adjacent to the first and second domains and comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a second C-type lectin receptor (CLR) capable of binding to its ligand.
[0078] In embodiments, the first C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Clec7a, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the first C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Clec7a, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 59.
[0079] In embodiments, the second C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Clec7a, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Clec7a, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 59.
[0080] In embodiments, the first C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Langerin, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 60. In embodiments, the first C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Langerin, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 61.
[0081] In embodiments, the second C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Langerin, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 60. In embodiments, the second C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Langerin, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 61.
[0082] In embodiments, the first C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of DC-SIGN, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 62. In embodiments, the first C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of DC-SIGN, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 63.
[0083] In embodiments, the second C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of DC-SIGN, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 62. In embodiments, the second C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of DC-SIGN, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 63.
[0084] In embodiments, the first C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Dectin-2, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 64. In embodiments, the first C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Dectin-2, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 65.
[0085] In embodiments, the second C-type lectin receptor (CLR) portion comprises the extracellular domain (ECD) of Dectin-2, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 64. In embodiments, the second C-type lectin receptor (CLR) portion comprises the C-type lectin binding domain (CLD) of Dectin-2, which has an amino acid sequence that is at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identical to the amino acid sequence of SEQ ID NO: 65.
[0086] In various embodiments, the heterologous chimeric protein of the present disclosure comprises an extracellular domain of human CD69 comprising the following amino acid sequence, or the isolated polynucleotide encoding the heterologous chimeric protein encodes an extracellular domain of human CD69 comprising the following amino acid sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGD (SEQ ID NO: 80).
[0087] In various embodiments, the heterologous chimeric protein used in the methods of the present disclosure comprises a variant of the extracellular domain of CD69. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80% identical to SEQ ID NO: 80. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0088] In various embodiments, the first domain of the heterologous chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:80.
[0089] In various embodiments, the heterologous chimeric protein comprises substantially the entire extracellular domain of CD69.
[0090] Those skilled in the art will be familiar with the literature, for example Llera et al., Crystal Structure of the C-Type Lectin-Like Domain from the Human Hematopoietic Cell Receptor CD69, J Biol Chem276(10):7312-7319(2001); Natarajan et al., Crystal structure of human CD69:a C-type lectin-like activation marker of hematopoietic cells,Biochemistry39:14779-14786(2000);Vanek et al.,Soluble reformed to have an exception physical and chemical stable display prolonged circulation and remain intact in the blood of mice,FEBS J275:5589-5606(2008);Kolenko et al.,The high-resolution structure of the extracellular domain of human CD69 using a novel polymer,Acta Crystallogr Sect F Struct Biol Cryst Commun 65:1258-1260 (2009), each of which is incorporated by reference in its entirety, can be used to select variants of the known amino acid sequence of CD69.
[0091] Linker In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, comprising a portion of a tumor necrosis factor receptor (TNFR2) and a portion of a C-type lectin receptor (CLR) flanked by a linker. In various embodiments, the linker comprises at least one cysteine residue capable of forming a disulfide bond. The at least one cysteine residue is capable of forming a disulfide bond between one pair (or more) of the chimeric proteins. Without being bound by theory, such disulfide bond formation is responsible for maintaining a useful multimeric state of the chimeric protein. This allows for efficient production of the chimeric protein, which enables desired activity in vitro and in vivo.
[0092] In various embodiments, the linker is not a single amino acid linker, for example, but not limited to, the linker is longer than one amino acid. In various embodiments, the linker is 1-6 amino acids in length or more, for example, but not limited to, the linker is 7 amino acids in length or more. In various embodiments, the linker includes more than one glycine residue.
[0093] In embodiments, in the chimeric proteins of the present disclosure, the linker is a polypeptide selected from a flexible amino acid sequence, an IgG hinge region, or an antibody sequence. In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4, optionally human IgG4. In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG1, optionally human IgG1.
[0094] In various embodiments, the linker may be derived from a naturally occurring multidomain protein or may be an empirical linker, such as those described in Chichili et al., (2013), Protein Sci. 22(2):153-167, Chen et al., (2013), Adv Drug Deliv Rev. 65(10):1357-1369 (the entire contents of which are incorporated herein by reference). In various embodiments, the linker may be designed using linker design databases and computer programs, such as those described in Chen et al., (2013), Adv Drug Deliv Rev. 65(10):1357-1369, and Crasto et al., (2000), Protein Eng. 13(5):309-312 (the entire contents of which are incorporated herein by reference).
[0095] In embodiments, the linker is a synthetic linker, such as PEG.
[0096] In various embodiments, the linker comprises a polypeptide. In various embodiments, the polypeptide is less than about 500, 450, 400, 350, 300, 250, 200, 150, or 100 amino acids in length. For example, the linker can be less than about 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 amino acids in length.
[0097] In embodiments, the linker is flexible.
[0098] In embodiments, the linker is rigid.
[0099] In various embodiments, the linker consists essentially of glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine).
[0100] In various embodiments, the linker comprises the hinge region of an antibody (e.g., IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2)). The hinge region found in IgG, IgA, IgD, and IgE class antibodies functions as a flexible spacer, allowing the Fab portion to move freely in space. In contrast to constant regions, hinge domains are structurally diverse, differing in both sequence and length between immunoglobulin classes and subclasses. For example, the length and flexibility of the hinge region differ between IgG subclasses. The hinge region of IgG1 encompasses amino acids 216-231 and is freely flexible, allowing the Fab fragment to rotate around its axis of symmetry and move within a sphere centered around the first of the two inter-heavy chain disulfide bridges. IgG2 has a shorter hinge than IgG1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks glycine residues, is relatively short, and contains a rigid polyproline double helix stabilized by additional inter-heavy chain disulfide bridges. These properties limit the flexibility of the IgG2 molecule. IgG3 differs from other subclasses in its unique extended hinge region (approximately four times longer than the IgG1 hinge), which contains 62 amino acids (including 21 prolines and 11 cysteines) and forms a rigid polyproline double helix. In IgG3, the Fab fragment is relatively far from the Fc fragment, increasing the molecular flexibility. The elongated hinge in IgG3 also accounts for its high molecular weight compared to other subclasses. The hinge region of IgG4 is shorter than that of IgG1, and its flexibility is intermediate between that of IgG1 and IgG2. The flexibility of the hinge region has been reported to decrease in the order IgG3 > IgG1 > IgG4 > IgG2. In embodiments, the linker is derived from human IgG4 and may contain one or more mutations to enhance dimer formation (including S228P) or FcRn binding.
[0101] According to crystallographic studies, the immunoglobulin hinge region can be further subdivided functionally into three regions: the upper hinge region, the core region, and the lower hinge region. See Shin et al., 1992 Immunological Reviews 130:87. The upper hinge region contains C H1 The length of the upper hinge region correlates with the segmental flexibility of the antibody. The core hinge region contains the inter-heavy chain disulfide bridges, while the lower hinge region is the C H2 It binds to the amino terminus of the domain and H2 (Ibid.) The core hinge region of wild-type human IgG1 contains the sequence CPPC (SEQ ID NO: 24), which, when dimerized by disulfide bond formation, results in a cyclic octapeptide that is thought to act as a pivot, thus providing flexibility. In embodiments, the linkers of the invention comprise one, two, or three of the upper hinge region, core region, and lower hinge region of any antibody (e.g., IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2)). The hinge region may also contain one or more glycosylation sites, which contain several structurally distinct types of sites for carbohydrate attachment. For example, IgA1 contains five glycosylation sites within a 17-amino acid segment of the hinge region, conferring resistance of the hinge region polypeptide to intestinal proteases, a property considered advantageous for secretory immunoglobulins. In embodiments, a linker of the present disclosure comprises one or more glycosylation sites.
[0102] In various embodiments, the linker comprises an Fc domain of an antibody (eg, IgG, IgA, IgD, and IgE, including subclasses (eg, IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2)).
[0103] In the chimeric proteins of the present disclosure, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4. In various embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human IgG4. In various embodiments, the linker has at least about 95%, or at least about 97%, or at least about 97%, or at least about 98% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-3 or SEQ ID NO: 73, e.g., at least 95% identical to the amino acid sequence of SEQ ID NO: 73. In various embodiments, the linker comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs: 4-50 (or variants thereof). In various embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50 (or a variant thereof), and one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0104] In various embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from a human IgG1 antibody. In various embodiments, the Fc domain exhibits increased affinity and enhanced binding to the fetal Fc receptor (FcRn). In various embodiments, the Fc domain comprises one or more mutations that increase affinity for and enhance binding to FcRn. Without being bound by theory, it is believed that the increased affinity and enhanced binding to FcRn increases the in vivo half-life of the chimeric proteins of the invention.
[0105] In various embodiments, the Fc domain in the linker comprises one or more amino acid substitutions at amino acid residues 250, 252, 254, 256, 308, 309, 311, 416, 428, 433, or 434 (according to Kabat numbering as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference), or their equivalents. In various embodiments, the amino acid substitution at amino acid residue 250 is with glutamine. In various embodiments, the amino acid substitution at amino acid residue 252 is with tyrosine, phenylalanine, tryptophan, or threonine. In various embodiments, the amino acid substitution at amino acid residue 254 is with threonine. In embodiments, the amino acid substitution at amino acid residue 256 is with serine, arginine, glutamine, glutamic acid, aspartic acid, or threonine. In embodiments, the amino acid substitution at amino acid residue 308 is with threonine. In embodiments, the amino acid substitution at amino acid residue 309 is with proline. In embodiments, the amino acid substitution at amino acid residue 311 is with serine. In embodiments, the amino acid substitution at amino acid residue 385 is with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine, or glycine. In embodiments, the amino acid substitution at amino acid residue 386 is with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine. In embodiments, the amino acid substitution at amino acid residue 387 is with arginine, proline, histidine, serine, threonine, or alanine. In embodiments, the amino acid substitution at amino acid residue 389 is with proline, serine, or asparagine. In embodiments, the amino acid substitution at amino acid residue 416 is with serine. In embodiments, the amino acid substitution at amino acid residue 428 is with leucine.In embodiments, the amino acid substitution at amino acid residue 433 is with arginine, serine, isoleucine, proline, or glutamine. In embodiments, the amino acid substitution at amino acid residue 434 is with histidine, phenylalanine, or tyrosine.
[0106] In embodiments, the Fc domain linker (e.g., comprising an IgG constant region) comprises one or more mutations, such as substitutions at amino acid residues 252, 254, 256, 433, 434, or 436 (according to Kabat numbering, as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference). In embodiments, the IgG constant region comprises a triple M252Y / S254T / T256E mutation or a YTE mutation. In embodiments, the IgG constant region comprises a triple H433K / N434F / Y436H mutation or a KFH mutation. In embodiments, the IgG constant region comprises a combination of YTE and KFH mutations.
[0107] In embodiments, the linker comprises an IgG constant region comprising one or more mutations at amino acid residues 250, 253, 307, 310, 380, 428, 433, 434, and 435 (according to Kabat numbering, as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference). Exemplary mutations include T250Q, M428L, T307A, E380A, I253A, H310A, M428L, H433K, N434A, N434F, N434S, and H435A. In embodiments, the IgG constant region comprises an M428L / N434S mutation or an LS mutation. In embodiments, the IgG constant region comprises T250Q / M428L mutations or QL mutations. In embodiments, the IgG constant region comprises an N434A mutation. In embodiments, the IgG constant region comprises T307A / E380A / N434A mutations or AAA mutations. In embodiments, the IgG constant region comprises I253A / H310A / H435A mutations or IHH mutations. In embodiments, the IgG constant region comprises H433K / N434F mutations. In embodiments, the IgG constant region comprises a combination of M252Y / S254T / T256E and H433K / N434F mutations.
[0108] Additional exemplary mutations in IgG constant regions are described, for example, in Robbie, et al., Antimicrobial Agents and Chemotherapy (2013), 57(12):6147-6153, Dall'Acqua et al., JBC (2006), 281(33):23514-24, Dall'Acqua et al., Journal of Immunology (2002), 169:5171-80, Ko et al. Nature (2014) 514:642-645, Grevys et al. Journal of Immunology. (2015), 194(11):5497-508, and U.S. Patent No. 7,083,784, the entire contents of which are incorporated herein by reference.
[0109] In various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 73 (see table below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. In various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 1 (see table below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. In various embodiments, mutations are made to SEQ ID NO: 1 to increase stability and / or half-life. For example, in various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO:2 (see table below), or an amino acid sequence at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. An exemplary Fc stabilizing mutant is S228P. Exemplary Fc half-life extending mutants are T250Q, M428L, V308T, L309P, and Q311S, and the linkers of the invention may comprise one, two, three, four, or five of these mutants.
[0110] In various embodiments, the chimeric protein binds to FcRn with high affinity. In various embodiments, the chimeric protein has a K of about 1 nM to about 80 nM. D For example, the chimeric protein may bind to FcRn with a K of about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 35 nM, about 40 nM, about 45 nM, about 50 nM, about 55 nM, about 60 nM, about 65 nM, about 70 nM, about 71 nM, about 72 nM, about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 nM, about 78 nM, about 79 nM, or about 80 nM. D In various embodiments, the chimeric protein may bind to FcRn with a K of about 9 nM.D In various embodiments, the chimeric protein does not substantially bind to other Fc receptors (i.e., other than FcRn) that have effector function.
[0111] In embodiments, the Fc domain of the linker has the amino acid sequence of SEQ ID NO: 1 (see Table 1 below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. In embodiments, mutations are made to SEQ ID NO: 1 to increase stability and / or half-life. For example, in embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 2 (see Table 1 below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. For example, in various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 3 (see Table 1 below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. For example, in various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 73 (see Table 1 below), or an amino acid sequence that is at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto.
[0112] In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1. For example, in various embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 73 (see Table 1 below), or an amino acid sequence at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. In various embodiments, the IgG1 is human IgG1. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG4. In various embodiments, the IgG4 is human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 73. In various embodiments, the linker further comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs: 4-50. In various embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50, and one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0113] In embodiments, the Fc domain comprises a mammalian Fc domain. In embodiments, the Fc domain comprises an Fc domain selected from a human Fc domain, a mouse Fc domain, a rat Fc domain, a sheep Fc domain, a goat Fc domain, a donkey Fc domain, a cat Fc domain, a hamster Fc domain, a guinea pig Fc domain, a horse Fc domain, a rabbit Fc domain, a pig Fc domain, a dog Fc domain, and a bovine Fc domain. In embodiments, the Fc domain comprises a human Fc domain, optionally comprising one or more mutations that extend serum half-life (e.g., M252Y, S254T, and T256E), promote dimerization (e.g., S228P or knob-in-hole mutations), reduce Fc effector function (e.g., L234A and L235A mutations (LALA) with or without a P329G mutation), and / or enhance binding to the fetal Fc receptor (FcRn). In embodiments, the Fc domain of the linker comprises the amino acid sequence of SEQ ID NO: 73 (see Table 1 below), or an amino acid sequence at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical thereto. In embodiments, the Fc domain comprises an Fc domain selected from an IgG Fc domain, an IgA Fc domain, an IgM Fc domain, an IgE Fc domain, and an IgD Fc domain. In embodiments, the IgG Fc domain is selected from an IgG1 Fc domain, an IgG2 Fc domain, an IgG3 Fc domain, and an IgG4 Fc domain. In embodiments, the IgA is selected from IgA1 and IgA2.
[0114] Additionally, one or more conjugated linkers can be used to connect the Fc domain (e.g., one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 73, or at least 90%, 93%, 95%, 97%, 98%, or 99% identical thereto) and the extracellular domain of the linker. For example, any one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or a variant thereof, can connect the extracellular domain disclosed herein and the Fc domain in the linker disclosed herein. Optionally, any one of SEQ ID NOs: 4-50, or a variant thereof, is positioned between the extracellular domain disclosed herein and the Fc domain disclosed herein. In various embodiments, the chimeric proteins of the invention may comprise variants of the conjugated linkers disclosed in Table 1 below. For example, the linker is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or may have at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0115] In embodiments, the first and second attachment linkers may be different, or they may be the same.
[0116] Without being bound by theory, the inclusion of a linker comprising at least a portion of the Fc domain in the chimeric protein helps to avoid the formation of insoluble and potentially non-functional protein concatamers and / or aggregates due to the presence of cysteines within the Fc domain that can form disulfide bonds between the chimeric proteins.
[0117] In various embodiments, the chimeric protein may include one or more attachment linkers as disclosed herein, and may lack an Fc domain linker as disclosed herein.
[0118] In various embodiments, the first and / or second attachment linker are independently selected from the amino acid sequences of SEQ ID NOs: 4-50, and are provided in Table 1 below: [Table 1-1] [Table 1-2] [Table 1-3]
[0119] In embodiments, the attached linker comprises substantially glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine). For example, in embodiments, the attached linker comprises (Gly4Ser) nwherein n is from about 1 to about 8, e.g., 1, 2, 3, 4, 5, 6, 7, or 8 (SEQ ID NOs: 25 through 32, respectively). In various embodiments, the conjugated linker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 33). Additional exemplary conjugated linkers include, but are not limited to, the sequences LE, (EAAAK) n (n = 1 to 3) (SEQ ID NO: 36 to SEQ ID NO: 38), A(EAAAK) n A (n = 2 to 5) (SEQ ID NOs: 39 to 42), A(EAAAK)ALEA(EAAAK)A (SEQ ID NO: 43), PAPAP (SEQ ID NO: 44), KESGSVSSEQLAQFRSLD (SEQ ID NO: 45), GSAGSAAGSGEF (SEQ ID NO: 46), and X represents any amino acid, such as Ala, Lys, or Glu (XP). n In embodiments, the bonded linker is GGS. In embodiments, the bonded linker is a linker having the sequence (Gly) n where n is any number from 1 to 100, for example, (Gly) 8 (SEQ ID NO: 34) and (Gly) 6 (SEQ ID NO: 35).
[0120] In various embodiments, the bonded linker is one or more of GGGSE (SEQ ID NO: 47), GSESG (SEQ ID NO: 48), GSEGS (SEQ ID NO: 49), GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS (SEQ ID NO: 50), and bonded linkers of G, S, and E randomly spaced every 4 amino acid interval.
[0121] The combination of a first binding linker, an Fc domain linker, and a second binding linker is referred to herein as a "modular linker." In various embodiments, the heterologous chimeric protein comprises a modular linker as shown in Table 2. [Table 2-1] [Table 2-2]
[0122] In various embodiments, the heterologous chimeric proteins of the invention may comprise variants of the modular linkers disclosed above in Table 2. For example, the linker is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 7 ... or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0123] In embodiments, the linker may be flexible, including but not limited to, highly flexible. In embodiments, the linker may be rigid, including but not limited to, a rigid alpha helix. Characteristics of exemplary bond linkers are shown in Table 3 below. [Table 3]
[0124] In various embodiments, the linker may be functional. For example, without limitation, the linker may function to improve folding and / or stability, improve expression, improve pharmacokinetics, and / or improve biological activity of the heterologous chimeric protein of the present invention. In another example, the linker may function to target the heterologous chimeric protein to a particular cell type or location.
[0125] In various embodiments, the heterologous chimeric protein comprises only one attachment linker.
[0126] In embodiments, the heterologous chimeric protein lacks a binding linker.
[0127] In embodiments, the linker is a synthetic linker, such as polyethylene glycol (PEG).
[0128] In various embodiments, a heterologous chimeric protein has a first domain capable of sterically binding its ligand / receptor and / or a second domain capable of sterically binding its ligand / receptor. Thus, there is sufficient overall flexibility in the chimeric protein and / or physical distance between the extracellular domain (or a portion thereof) and the rest of the chimeric protein such that the ligand / receptor-binding domain of the extracellular domain is not sterically hindered from binding its ligand / receptor. This flexibility and / or physical distance (referred to as "slack") may typically be present in the extracellular domain(s), typically be present in the linker, and / or typically be present in the chimeric protein (as a whole). Alternatively or additionally, an amino acid sequence (for example) may be added to one or more extracellular domains and / or linkers to provide the slack necessary to avoid steric hindrance. Any amino acid sequence that provides slack may be added. In various embodiments, the added amino acid sequence may be the sequence (Gly) nwhere n is any number from 1 to 100. Additional examples of amino acid sequences that can be added include the conjugated linkers described in Tables 1 and 3. In various embodiments, a polyethylene glycol (PEG) linker can be added between the extracellular domain and the linker to provide the necessary slack to avoid steric hindrance. Such PEG linkers are well known in the art.
[0129] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains and optionally comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand.
[0130] In various embodiments, the first domain comprises a portion of TNFR2 comprising the extracellular domain of TNFR2 or a fragment thereof. In various embodiments, the portion of TNFR2 comprises an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57, and capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor. In various embodiments, the portion of the CLR comprises the extracellular domain of the CLR, or a fragment thereof capable of binding to a natural ligand of the CLR. In various embodiments, the portion of the CLR comprises an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to an amino acid sequence selected from SEQ ID NOs: 58-65. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In embodiments, the linker further comprises one or more coupled linkers, wherein such coupled linkers are independently selected from SEQ ID NOs:4-50. In embodiments, the linker comprises two or more coupled linkers, each coupled linker independently selected from SEQ ID NOs:4-50, wherein one coupled linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other coupled linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0131] In embodiments, when a chimeric protein comprises a portion of TNFR2, a connecting linker before the Fc domain, an Fc domain, a connecting linker after the Fc domain, and a portion of Clec7a, the chimeric protein can comprise the following structure: TNFR2 ECD-Fc domain-linker-Clec7a fragment
[0132] In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57; a portion of Clec7a capable of binding to β-1,3-linked and / or β-1,6-linked glucan and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 59; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 73. In embodiments, the linker further comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs: 4-50. In embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50, wherein one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0133] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with cellular TNF receptors, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of C-type lectin domain-containing 7A (Clec7A) capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
[0134] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57, and (b) is a hinge-CH2-CH3 domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73. (c) is a linker flanking the first and second domains, each containing an Fc domain; and (c) is a second domain comprising a portion of the C-type lectin binding domain (CLD) of C-type lectin domain-containing 7A (Clec7A) capable of binding to a ligand containing a β-1,3-linked and / or β-1,6-linked glucan, and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 59.
[0135] An exemplary TNFR2-Fc-Clec7a chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the extracellular domain of Clec7a is shown in italic font): [ka]
[0136] In various embodiments, the chimeric protein comprises a variant of a TNFR2-Fc-Clec7a chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0137] An exemplary TNFR2-Fc-Clec7a chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the C-type lectin binding domain (CLD) of Clec7a is shown in italic font): [ka]
[0138] In various embodiments, the chimeric protein comprises a variant of a TNFR2-Fc-Clec7a chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0139] An exemplary mouse TNFR2-Fc-Clec7a chimeric protein has the following sequence (the extracellular domain of mouse TNFR2 is underlined, the linker comprising the mutated Fc domain of mouse IgG1 is in bold font, the connecting linker is in underlined bold italic font, and the extracellular domain of Clec7a is in italic font): [ka]
[0140] In various embodiments, the chimeric protein comprises a variant of the murine TNFR2-Fc-Clec7a chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81% identical to SEQ ID NO: 81. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0141] In various embodiments, when a chimeric protein comprises a portion of the extracellular domain (ECD) of TNFR2, a binding linker before the Fc domain, an Fc domain, a binding linker after the Fc domain, and a portion of Langerin, the chimeric protein can comprise the following structure: TNFR2 ECD-Fc domain-linker-part of Langerin
[0142] In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57; a portion of ranglin capable of binding to a ligand comprising a sulfated glycan, a mannosylated glycan, keratan sulfate (KS), and / or β-glucan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 60 or SEQ ID NO: 61; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 73. In embodiments, the linker further comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs: 4-50. In embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50, wherein one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0143] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with cellular TNF receptors, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans.
[0144] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73; and (c) is a second domain comprising a portion of the extracellular domain of Langerin capable of binding to a ligand comprising a sulfated glycan, a mannosylated glycan, keratan sulfate (KS), and / or a β-glucan, and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61.
[0145] An exemplary TNFR2-Fc-Langerin chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the extracellular domain of Langerin is shown in italic font): [ka]
[0146] In various embodiments, the chimeric protein comprises a variant of a TNFR2-Fc-Langerin chimeric protein. By way of example, the variant has an affinity to SEQ ID NO: 68, which is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0147] An exemplary TNFR2-Fc-Langerin chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the C-type lectin binding domain (CLD) of Langerin is shown in italic font): [ka]
[0148] In various embodiments, the chimeric protein comprises a variant of a TNFR2-Fc-Langerin chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0149] An exemplary mouse TNFR2-Fc-Langerin chimeric protein has the following sequence (the extracellular domain of mouse TNFR2 is underlined, the linker comprising the mutated Fc domain of mouse IgG1 is in bold font, the connecting linker is in underlined bold italic font, and the extracellular domain of Langerin is in italic font): [ka]
[0150] In various embodiments, the chimeric protein comprises a variant of a murine TNFR2-Fc-Langerin chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0151] In various embodiments, when a chimeric protein comprises the extracellular domain (ECD) of TNFR2, a binding linker before the Fc domain, an Fc domain, a binding linker after the Fc domain, and a portion of DC-SIGN, the chimeric protein can comprise the following structure: TNFR2 ECD-Fc domain-binding linker-part of DC-SIGN
[0152] In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of DC-SIGN comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73. In various embodiments, the linker further comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs:4-50. In various embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50, and one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0153] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
[0154] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73; and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3), and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63.
[0155] An exemplary TNFR2-Fc-DC-SIGN chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the extracellular domain of DC-SIGN is shown in italic font): [ka]
[0156] In various embodiments, the chimeric protein comprises a variant of the TNFR2-Fc-DC-SIGN chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0157] An exemplary TNFR2-Fc-DC-SIGN chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the conjugated linker is shown in underlined bold italic font, and the C-type lectin binding domain (CLD) of DC-SIGN is shown in italic font): [ka]
[0158] In various embodiments, the chimeric protein comprises a variant of the TNFR2-Fc-DC-SIGN chimeric protein. By way of example, the variant has a similar affinity to SEQ ID NO: 71, at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0159] An exemplary mouse TNFR2-Fc-DC-SIGN chimeric protein has the following sequence (the extracellular domain of mouse TNFR2 is underlined, the linker comprising the mutated Fc domain of mouse IgG1 is in bold font, the connecting linker is in underlined bold italic font, and the extracellular domain of DC-SIGN is in italic font): [ka]
[0160] In various embodiments, the chimeric protein comprises a variant of a murine TNFR2-Fc-DC-SIGN chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0161] In various embodiments, when a chimeric protein comprises the extracellular domain (ECD) of TNFR2, a binding linker before the Fc domain, an Fc domain, a binding linker after the Fc domain, and a portion of Dectin-2, the chimeric protein may comprise the following structure: TNFR2 ECD-Fc domain-binding linker - part of Dectin-2
[0162] In various embodiments, the chimeric protein comprises an extracellular domain of TNFR2 comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of Dectin-2 comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:65; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In various embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In various embodiments, the linker further comprises one or more bonded linkers, wherein such bonded linkers are independently selected from SEQ ID NOs:4-50. In various embodiments, the linker comprises two or more bonded linkers, each bonded linker independently selected from SEQ ID NOs: 4-50, and one bonded linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other bonded linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0163] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Dectin-2 capable of binding to α-mannan.
[0164] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73; and (c) is a second domain comprising a portion of the extracellular domain of Dectin-2 capable of binding to a ligand comprising α-mannan, and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:65.
[0165] An exemplary TNFR2-Fc-Dectin2 chimeric protein has the following sequence (the extracellular domain of TNFR2 is underlined, the linker comprising the mutated Fc domain of human IgG1 is shown in bold font, the mutations are underlined, the connecting linker is shown in underlined bold italic font, and the C-type lectin binding domain (CLD) of Dectin-2 is shown in italic font): [ka]
[0166] In various embodiments, the chimeric protein comprises a variant of a TNFR2-Fc-Dectin2 chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0167] An exemplary mouse TNFR2-Fc-Dectin2 chimeric protein has the following sequence (the extracellular domain of mouse TNFR2 is underlined, the linker comprising the mutated Fc domain of mouse IgG1 is in bold font, the connecting linker is in underlined bold italic font, and the extracellular domain of Dectin2 is in italic font): [ka]
[0168] In various embodiments, the chimeric protein comprises a variant of a murine TNFR2-Fc-Dectin2 chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0169] In embodiments, when a chimeric protein comprises a portion of Langerin, a connecting linker before the Fc domain, an Fc domain, a connecting linker after the Fc domain, and a portion of Clec7a, the chimeric protein can comprise the following structure: Part of Langerin-Fc domain-linker-part of Clec7a
[0170] In various embodiments, the chimeric protein comprises: a portion of Langerin capable of binding to a ligand comprising a sulfated glycan, a mannosylated glycan, a keratan sulfate (KS), and / or a β-glucan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61; a portion of Clec7a capable of binding to a β-1,3-linked and / or a β-1,6-linked glucan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In embodiments, the linker further comprises one or more coupled linkers, wherein such coupled linkers are independently selected from SEQ ID NOs:4-50. In embodiments, the linker comprises two or more coupled linkers, each coupled linker independently selected from SEQ ID NOs:4-50, wherein one coupled linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other coupled linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0171] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans; (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain; and (c) is a second domain comprising a portion of the extracellular domain of Clec7a capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
[0172] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS), and / or β-glucans and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:73; and (c) is a second domain comprising a portion of the extracellular domain of Clec7a capable of binding to β-1,3-linked and / or β-1,6-linked glucans and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59.
[0173] An exemplary Langerin-Fc-Clec7a chimeric protein has the following sequence (the extracellular domain of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the connecting linker is in underlined bold italic font, and the extracellular domain of Clec7a is in italic font): [ka]
[0174] In various embodiments, the chimeric protein comprises a variant of a Langerin-Fc-Clec7a chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0175] An exemplary Langerin (CLD)-Fc-Clec7a (CLD) chimeric protein has the following sequence (the C-type lectin binding domain of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the binding linker is in underlined bold italic font, and the C-type lectin binding domain of Clec7a (CLD) is in italic font): [ka]
[0176] In various embodiments, the chimeric protein comprises a variant of a Langerin-Fc-Clec7a chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0177] In various embodiments, when a chimeric protein comprises a portion of Langerin, a binding linker before the Fc domain, an Fc domain, a binding linker after the Fc domain, and a portion of DC-SIGN, the chimeric protein can comprise the following structure: Part of Langerin-Fc domain-binding linker-part of DC-SIGN
[0178] In various embodiments, the chimeric protein comprises: a portion of Langerin capable of binding to a ligand comprising a sulfated glycan, a mannosylated glycan, a keratan sulfate (KS), and / or a beta-glucan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61; a portion of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3), and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In embodiments, the linker further comprises one or more coupled linkers, wherein such coupled linkers are independently selected from SEQ ID NOs:4-50. In embodiments, the linker comprises two or more coupled linkers, each coupled linker independently selected from SEQ ID NOs:4-50, wherein one coupled linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other coupled linker is C-terminal to the hinge-CH2-CH3 Fc domain. In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
[0179] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans, and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 62 or SEQ ID NO: 63; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 73; and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3), and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 62 or SEQ ID NO: 63.
[0180] An exemplary Langerin-Fc-DC-SIGN chimeric protein has the following sequence (the extracellular domain of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the connecting linker is in underlined bold italic font, and the extracellular domain of DC-SIGN is in italic font): [ka]
[0181] In various embodiments, the chimeric protein comprises a variant of the Langerin-Fc-DC-SIGN chimeric protein. By way of example, the variant has a similar affinity to SEQ ID NO: 76, at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0182] An exemplary Langerin (CLD)-Fc-DC-SIGN (CLD) chimeric protein has the following sequence (the C-type lectin binding domain of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the binding linker is in underlined bold italic font, and the C-type lectin binding domain (CLD) of DC-SIGN is in italic font): [ka]
[0183] In various embodiments, the chimeric protein comprises a variant of the Langerin-Fc-DC-SIGN chimeric protein. By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0184] In various embodiments, when a chimeric protein comprises a portion of Langerin, a binding linker before the Fc domain, an Fc domain, a binding linker after the Fc domain, and a portion of Dectin-2, the chimeric protein can comprise the following structure: Part of Langerin-Fc domain-binding linker-part of Dectin-2
[0185] In various embodiments, the chimeric protein comprises: a portion of Langerin capable of binding to a ligand comprising a sulfated glycan, a mannosylated glycan, a keratan sulfate (KS), and / or a β-glucan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 60 or SEQ ID NO: 61; a portion of Dectin-2 capable of binding to α-mannan, and comprising an amino acid sequence at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 65; and a linker adjacent to the extracellular domain. In various embodiments, the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, e.g., human IgG1 or human IgG4. In embodiments, the hinge-CH2-CH3 Fc domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:73. In embodiments, the linker further comprises one or more coupled linkers, wherein such coupled linkers are independently selected from SEQ ID NOs:4-50. In embodiments, the linker comprises two or more coupled linkers, each coupled linker independently selected from SEQ ID NOs:4-50, wherein one coupled linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other coupled linker is C-terminal to the hinge-CH2-CH3 Fc domain.
[0186] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Dectin-2 capable of binding to α-mannan.
[0187] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS), and / or β-glucans, and comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 65; (b) is a linker flanking the first domain and the second domain, comprising a hinge-CH2-CH3 Fc domain comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 73; and (c) is a second domain comprising a portion of the extracellular domain of Dectin-2 capable of binding to α-mannan, and comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 65.
[0188] An exemplary Langerin-Fc-Dectin2 chimeric protein has the following sequence (the extracellular domain of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the connecting linker is in underlined bold italic font, and the extracellular domain of Dectin2 is in italic font): [ka]
[0189] In various embodiments, the chimeric protein comprises a variant of a Langerin-Fc-Dectin2 chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0190] An exemplary Langerin (CLD)-Fc-Dectin2 chimeric protein has the following sequence (the C-type lectin binding domain (CLD) of Langerin is underlined, the linker comprising the mutated Fc domain of human IgG1 is in bold font, the mutations are underlined, the connecting linker is in underlined bold italic font, and the extracellular domain of Dectin2 is in italic font): [ka]
[0191] In various embodiments, the chimeric protein comprises a variant of a Langerin-Fc-Dectin2 chimeric protein. By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79% identical to SEQ ID NO: 79. 9%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.
[0192] Nucleic acids encoding chimeric proteins of the present disclosure In various aspects, the present disclosure provides an isolated nucleic acid encoding any of the chimeric proteins disclosed herein, or any component thereof.
[0193] In one aspect, the disclosure relates to an isolated polynucleotide encoding a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of tumor necrosis factor (TNF) receptor 2 (TNFR2), or a variant or fragment thereof capable of binding to a TNFR2 ligand, and (c) is CLEC7a or a variant or fragment thereof capable of binding to a CLEC7a ligand, DC-SIGN (CD209), or a variant thereof capable of binding to a DC-SIGN (CD209) ligand. and (b) a second domain comprising an extracellular domain selected from the group consisting of a CLEC6A (Cell Signaling Cell Line) or a variant or fragment thereof capable of binding to a Dectin 2 (CLEC6A) ligand, a Langerin (CD207, CLC4K) or a variant or fragment thereof capable of binding to a Langerin (CD207, CLC4K) ligand, and a CD69. (b) is a linker flanking the first and second domains, the linker comprising at least one cysteine residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain. In some embodiments, the TNFR2 ligand is TNFα. In some embodiments, the CLEC7a ligand is a β-1,3-linked and / or β-1,6-linked glucan. In some embodiments, the DC-SIGN (CD209) ligand is intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3). In embodiments, the Dectin 2 (CLEC6A) ligand is alpha-mannan. In embodiments, the Langerin (CD207, CLC4K) ligand is a sulfated glycan, a mannosylated glycan, keratan sulfate (KS) and / or beta-glucan. In embodiments, the CD69 ligand is Galectin 1 (Gal-1) or the S100A8 / S100A9 complex. In embodiments, the isolated polynucleotide is or comprises mRNA. In embodiments, the isolated polynucleotide is or comprises mRNA modified according to any of the embodiments disclosed herein.
[0194] In one aspect, the present disclosure provides an isolated polynucleotide encoding, or a nucleic acid encoding, a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, optionally comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand. In various embodiments, the CLR is selected from C-type lectin domain-containing 7A (Clec7A), langerin, dendritic cell-specific intercellular adhesion molecule 3-binding nonintegrin (DC-SIGN), and dendritic cell-associated C-type lectin 2 (Dectin-2).
[0195] In one aspect, the disclosure provides an isolated polynucleotide encoding a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of C-type lectin domain-containing 7A (Clec7A) capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
[0196] In one aspect, the present disclosure provides an isolated polynucleotide encoding a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans.
[0197] In one aspect, the present disclosure provides an isolated polynucleotide encoding a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
[0198] In one aspect, the present disclosure provides an isolated polynucleotide encoding a chimeric protein, or a nucleic acid encoding a chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of the extracellular domain of TNF receptor 2 (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Dectin 2 capable of binding to α-mannan.
[0199] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of a first C-type lectin receptor (CLR) capable of binding to its ligand, (b) is a linker adjacent to the first and second domains and comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of a second C-type lectin receptor (CLR) capable of binding to its ligand.
[0200] In one aspect, the disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans; (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain; and (c) is a second domain comprising a portion of the extracellular domain of Clec7a capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
[0201] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of DC-SIGN capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
[0202] In one aspect, the present disclosure provides a chimeric protein, or a nucleic acid encoding the chimeric protein, having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising a portion of Langerin capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or β-glucans, (b) is a linker flanking the first and second domains, comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising a portion of the extracellular domain of Dectin-2 capable of binding to α-mannan.
[0203] In one aspect, the present disclosure provides an isolated polynucleotide encoding the chimeric protein of any of the embodiments disclosed herein.
[0204] In one aspect, the present disclosure provides a host cell comprising the vector of any of the embodiments disclosed herein. In one aspect, the present disclosure provides a host cell comprising RNA (e.g., but not limited to, mmRNA) encoding the chimeric protein of any of the embodiments disclosed herein. A host cell comprising a nucleic acid, e.g., mmRNA, of any of the embodiments disclosed herein. In embodiments, the polynucleotide is RNA, optionally mRNA. In embodiments, the polynucleotide is codon optimized.
[0205] In embodiments, the polynucleotide is or comprises mRNA or modified mRNA (mmRNA). In embodiments, the polynucleotide may comprise polynucleotide modifications, including, but not limited to, nucleoside modifications. In embodiments, the polynucleotide is or comprises mmRNA. In embodiments, the mmRNA comprises one or more nucleoside modifications. In embodiments, the nucleoside modifications are pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 5-methyluridine, 5-hydroxy ... Lysine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydro Rouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine Cytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine,4-Methoxy-pseudoisocytidine, 4-Methoxy-1-methyl-pseudoisocytidine, 2-Aminopurine, 2,6-Diaminopurine, 7-Deazaadenine, 7-Deaza-8-Azaadenine, 7-Deaza-2-Aminopurine, 7-Deaza-8-Aza-2-Aminopurine, 7-Deaza-2,6-Diaminopurine, 7-Deaza-8-Aza-2,6-Diaminopurine, 1-Methyladenosine N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine , 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine In some embodiments, the guanosine is selected from the group consisting of guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and combinations thereof.
[0206] In embodiments of the polypeptide, the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), 2-thiouridine (s2U), 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2'-O-methyluridine, 1-methyl-pseudouridine (m1Ψ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyanouridine, 4'-thiouridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-diaminopurine (I), 1-methylinosine (m1I), and 7-aminomethyl-7-deaza-guanosine (preQ), 7-cyano-7-deaza-guanosine (preQ), 7-aminomethyl-7-deaza-guanosine (preQ), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, and combinations of two or more thereof. In various embodiments, the mmRNA does not cause substantial induction of an innate immune response in cells into which the mmRNA is introduced. In various embodiments, the mmRNA is modified to improve one or more of the efficiency of chimeric protein production, intracellular retention of the mmRNA, and viability of contacted cells, and to reduce immunogenicity.
[0207] In various embodiments, the mmRNA has a length sufficient to include an open reading frame encoding a chimeric protein of the present disclosure.
[0208] Modified mRNA need not be uniformly modified throughout the entire length of the molecule. Different nucleotide modifications and / or backbone structures can be present at various positions within the nucleic acid. Those skilled in the art will understand that nucleotide analogs or other modification(s) can be placed at any position(s) of the nucleic acid so long as the function of the nucleic acid is not substantially reduced. The modification can be a 5'-end modification or a 3'-end modification. The nucleic acid can contain at least one and up to 100% modified nucleotides, or any intervening percentage, for example, at least about 50% modified nucleotides, at least about 80% modified nucleotides, or at least about 90% modified nucleotides.
[0209] In various embodiments, the mmRNA may contain modified pyrimidines such as uracil or cytosine. In various embodiments, at least about 5%, at least about 10%, at least about 25%, or at least about 50%, in various embodiments, the modified uracils may be substituted with a compound having a single unique structure, or with multiple compounds having different structures as disclosed above (e.g., the same mmRNA may contain two, three, four, or more uniquely modified uracils). In various embodiments, at least about 5%, at least about 10%, at least about 25%, at least about 50%, at least about 80%, at least about 90%, or 100% of the cytosines in the nucleic acid may be substituted with modified cytosines. The modified cytosines may be substituted with a compound having a single unique structure, or with multiple compounds having different structures as disclosed above (e.g., the same mmRNA may contain two, three, four, or more uniquely modified cytosines).
[0210] In various embodiments, the mmRNA comprises at least one chemically modified nucleoside. In embodiments, the at least one chemically modified nucleoside is pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), 2-thiouridine (s2U), 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2'-O-methyluridine, 1-methyl-pseudouridine (m1Ψ ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyanouridine, 4'-thiouridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-diaminopurine (I), 1-methylinosine (m1I), and iosine (imG), methylwiosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, and combinations of two or more thereof. In various embodiments, the mmRNA comprises at least one chemically modified nucleoside, wherein the at least one chemically modified nucleoside is selected from pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof. In various embodiments, the mmRNA comprises at least one chemically modified nucleoside that is N1-methylpseudouridine. In various embodiments, the mmRNA is fully modified with chemically modified uridines.In various embodiments, the mmRNA is fully modified N1-methylpseudouridine mRNA. Additional chemical modifications are disclosed in U.S. Patent Application Publication No. 20190111003, the entire contents of which are incorporated herein by reference.
[0211] In embodiments, the modified nucleoside is pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl- These include linomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine. In various embodiments, the modified nucleoside is 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.
[0212] In embodiments, the modified nucleoside is 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentyl)ade ... These include N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.
[0213] In various embodiments, modified nucleosides include inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.
[0214] In embodiments, the nucleotide may be modified in the major groove face and may include replacing the hydrogen on C-5 of uracil with a methyl or halo group.
[0215] In embodiments, the modified nucleoside is 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine, 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, or 5'-O-(1-thiophosphate)-pseudouridine.
[0216] Further examples of modified nucleotides and combinations of modified nucleotides can be found in U.S. Patent Nos. 8,710,200, 8,822,663, 8,999,380, 9,181,319, 9,254,311, 9,334,328, 9,464,124, 9,950,068, 10,626,400, 10,808,242, 11,020,477, U.S. Patent Application Publication Nos. 20220001026, 20210318817, and 2021028326. 2, 20200360481, 20200113844, 20200085758, 20170204152, 20190114089, 20190114090, 20180369374, 20180318385, 20190111003, and PCT International Application Nos. WO / 2017112943, WO2014 / 028429, and WO2017 / 201325, the entire contents of which are incorporated herein by reference. Methods for synthesizing modified mRNA are disclosed, for example, in U.S. Patent Application Publication No. 20170204152, the entire contents of which are incorporated herein by reference.
[0217] In various embodiments, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the cytosine residues in the mmRNA are substituted with modified cytosine residues. In various embodiments, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the uracil residues in the mmRNA are substituted with modified uracil residues.
[0218] In various embodiments, the mmRNA further comprises a 5' untranslated region (UTR) and / or a 3' UTR, either or both of which may independently comprise one or more different nucleoside modifications. In such embodiments, the nucleoside modifications may also be present in the translatable region. In various embodiments, the mmRNA further comprises a Kozak sequence. In various embodiments, the mmRNA further comprises an internal ribosome entry site (IRES).
[0219] In various embodiments, the mmRNA further comprises a 5' cap and / or a polyA tail.
[0220] In some embodiments, the 5' cap comprises a 5'-5'-triphosphate linkage between the 5'-terminal nucleotide and a guanine nucleotide. In some embodiments, the 5' cap comprises methylation of the last and penultimate 5' nucleotides on the 2' hydroxyl groups. In some embodiments, the 5' cap promotes binding of mRNA cap-binding protein (CBP), conferring mRNA stability and / or translation competence within the cell.
[0221] In embodiments, the length of the poly-A tail is greater than about 30 nucleotides, or greater than about 40 nucleotides. In embodiments, the length of the poly-A tail is at least about 40 nucleotides, or at least about 45 nucleotides, or at least about 55 nucleotides, or at least about 60 nucleotides, or at least about 80 nucleotides, or at least about 90 nucleotides, or at least about 100 nucleotides, or at least about 120 nucleotides, or at least about 140 nucleotides, or at least about 160 nucleotides, or at least about 180 nucleotides, or at least about 200 nucleotides, or at least about 250 nucleotides, or at least about 300 nucleotides, or at least about 350 nucleotides, or at least about 400 nucleotides, or at least about 450 nucleotides, or at least about 500 nucleotides, or at least about 600 nucleotides, or at least about 700 nucleotides, or at least about 800 nucleotides, or at least about 900 nucleotides, or at least about 1000 nucleotides.
[0222] In various embodiments, the mmRNA comprises a 3' untranslated region (UTR). In various embodiments, the 3' UTR comprises a nucleic acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence set forth in Table 4 of U.S. Patent Application Publication No. 20190114089, which is incorporated herein in its entirety. In various embodiments, the 3' UTR comprises at least one microRNA-122 (miR-122) binding site, wherein the miR-122 binding site is a miR-122-3p binding site or a miR-122-5 binding site. In various embodiments, the mmRNA comprises a nucleic acid sequence comprising a miRNA binding site. In some embodiments, the miRNA binding site binds to miR-122. In certain embodiments, the miRNA binding site binds to miR-122-3p or miR-122-5p. In various embodiments, the mmRNA comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten miRNA binding sites.
[0223] In some embodiments, the miRNA binding site is inserted within the 3'UTR. In some embodiments, the polynucleotide is DNA. In some embodiments, a spacer sequence is further included between the open reading frame and the miRNA binding site. In one aspect, the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.
[0224] In some embodiments, the mmRNA further comprises a 5'UTR. In some embodiments, the 5'UTR comprises a nucleic acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence set forth in Table 3 of U.S. Patent Application Publication No. 20190114089 or a sequence disclosed in PCT International Application Publication Nos. WO2017 / 201325 and WO2014 / 164253 (each of which is incorporated herein in its entirety). In some embodiments, the 5'UTR possesses a characteristic that plays a role in translation initiation. In some embodiments, the 5'UTR possesses a signature, such as a Kozak sequence, commonly known to be involved in the process by which ribosomes initiate translation of many genes. In some embodiments, the 5'UTR forms a secondary structure involved in the binding of elongation factors. In various embodiments, the 5'UTR of an mRNA known to be upregulated, such as c-myc, may be used to enhance expression of a nucleic acid molecule, such as a polynucleotide. In various embodiments, the 5'UTR of an mRNA known to be upregulated in the liver and / or spleen may be used to enhance expression of a nucleic acid molecule, such as a polynucleotide, in the liver and / or spleen.
[0225] In embodiments, at least one of the regions of linked nucleosides of A comprises a sequence of linked nucleosides that functions as a 5'UTR, and at least one of the regions of linked nucleosides of C comprises a sequence of linked nucleosides that functions as a 3'UTR. In embodiments, the 5'UTR and 3'UTR are derived from the same or different species. In embodiments, the 5'UTR and 3'UTR can be native untranslated regions from different proteins derived from the same or different species. In embodiments, the 5'UTR and 3'UTR can have synthetic sequences.
[0226] In various embodiments, the mmRNA further comprises a 3' polyadenylation (polyA tail).
[0227] In embodiments, the mmRNA further comprises a 5' end cap, which in embodiments is Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, a 5' methyl G cap, or an analog thereof.
[0228] In embodiments, the polynucleotide is in vitro transcribed (IVT). In embodiments, the polynucleotide is chimeric. In embodiments, the polynucleotide is circular.
[0229] In embodiments, the polynucleotide is or comprises DNA. In embodiments, the polynucleotide is or comprises a minicircle or plasmid DNA. In embodiments, the plasmid DNA is completely free of prokaryotic components. In embodiments, the polynucleotide comprises a tissue-specific regulatory element. In embodiments, the tissue-specific regulatory element is a promoter or enhancer. In embodiments, the plasmid DNA is an expression vector. In embodiments, the DNA is or comprises a minicircle. In embodiments, the minicircle is a circular molecule, which is optionally small. In embodiments, the minicircle utilizes cellular transcription and translation machinery to produce the encoded gene product. In embodiments, the minicircle is completely free of prokaryotic components. In embodiments, the minicircle comprises substantially only sequences of mammalian origin (or optimized for mammalian cells). In embodiments, the minicircle lacks or has reduced amounts of DNA sequence elements recognized by the innate immune system and / or Toll-like receptors. In embodiments, minicircles are generated by excising bacterial components from a parental plasmid, thereby making them smaller than the parental DNA sequence. In embodiments, the minicircle is of non-viral origin. In embodiments, the minicircle remains episomal. In embodiments, the minicircle is not replicated in the host cell. In embodiments, expression of the chimeric protein in non-dividing cells harboring the minicircle persists in dividing cells for at least 2 days, or at least 4 days, or at least 6 days, or at least 8 days, or at least 10 days, or at least 12 days, or at least 14 days, or at least 16 days, or at least 18 days, or at least 20 days, or at least 22 days, or at least 24 days, or longer.In various embodiments, expression of the chimeric protein in non-dividing cells harboring minicircles persists in dividing cells for at least 4 days, or at least 6 days, or at least 8 days, or at least 10 days, or at least 1 week, or at least 2 weeks, or at least 3 weeks, or at least 4 weeks, or at least 5 weeks, or at least 6 weeks, or at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months, or at least 8 months, or longer.
[0230] In various embodiments, the mmRNA of the present disclosure are produced by means available in the art, including, but not limited to, in vitro transcription (IVT) and synthetic methods. Enzymatic IVT, solid-phase, liquid-phase, hybrid synthesis, small-area synthesis, and ligation methods may be utilized. In various embodiments, the mmRNA is produced using IVT enzymatic synthesis. Methods for producing polynucleotides by IVT are known in the art and are described in International Application PCT International Patent Publication No. WO2013151666, the contents of which are incorporated herein by reference in their entirety. Accordingly, the present disclosure also includes polynucleotides, e.g., DNA, constructs, and vectors, that can be used to in vitro transcribe the mRNA described herein.
[0231] In embodiments, the polynucleotide is DNA. In embodiments, the polynucleotide comprises a skin-specific regulatory element. In various embodiments, the skin-specific regulatory element is a skin-specific promoter selected from the keratin 5 (K5) promoter, the keratin 6 (K6) promoter, the keratin 14 (K14) promoter, the keratin 16 (K16) promoter, the alpha 1 (I) collagen promoter, the filaggrin promoter, the loricrin promoter, the involucrin promoter, the tyrosinase promoter, and the alpha V integrin promoter, which can be constructed as described, for example, in U.S. Patent Application Publication Nos. 2002 / 0100068, 2003 / 0158137, 2005 / 0043235, 2007 / 0142282, 2008 / 0147045, 2010 / 0154068, and 2020 / 0085021, each of which is incorporated herein by reference in its entirety.
[0232] In one aspect, the present disclosure provides a vector comprising any one of the polynucleotides of the embodiments disclosed herein. In various embodiments, the chimeric protein can be provided as an expression vector. In various embodiments, the expression vector is a DNA expression vector or an RNA expression vector. In various embodiments, the expression vector is a viral expression vector. In various embodiments, the expression vector is a non-viral expression vector (for example, but not limited to, a plasmid).
[0233] In various embodiments, the non-viral vector is a linear or circular DNA molecule comprising a polynucleotide encoding a polypeptide and operably linked to a control sequence, which provides for expression of the polynucleotide encoding the polypeptide. In various embodiments, the non-viral vector comprises a promoter sequence and transcriptional and translational stop signal sequences. In various embodiments, expression vectors can include, among others, chromosomal and episomal vectors, such as vectors derived from bacterial plasmids, transposons, yeast episomes, insertion factors, yeast chromosomal elements, and combinations thereof. The construct can contain control regions that regulate and engender expression.
[0234] A vector generally comprises an isolated nucleic acid and can be used to deliver the isolated nucleic acid into a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. In various embodiments, the expression vector is an autonomously replicating plasmid or virus (e.g., an AAV vector). In various embodiments, the expression vector is a non-plasmid and non-viral compound that facilitates the transfer of nucleic acid into a cell, such as, for example, a polylysine compound or a liposome. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, and retroviral vectors.
[0235] In various embodiments, polynucleotide or cell therapy can employ an expression vector comprising an isolated polynucleotide encoding a chimeric protein operably linked to an expression control region that functions in a host cell. The expression control region can drive expression of the operably linked encoding nucleic acid such that the chimeric protein is produced in a human cell transformed with the expression vector. Expression control regions are regulatory polynucleotides (sometimes referred to herein as elements), such as promoters and enhancers, that affect the expression of an operably linked nucleic acid. The expression control region of an expression vector can express the operably linked encoding nucleic acid in a human cell. In one embodiment, an expression control region confers controllable expression to an operably linked nucleic acid. A signal (sometimes referred to as a stimulus) can increase or decrease the expression of a nucleic acid operably linked to such an expression control region. Such expression control regions that increase expression in response to a signal are often referred to as inducible. Such expression control regions that decrease expression in response to a signal are often referred to as repressible. In various embodiments, expression of the chimeric protein is inducible or repressible. Typically, the amount of increase or decrease conferred by such elements is proportional to the amount of signal present; the greater the amount of signal, the greater the increase or decrease in expression.
[0236] Expression systems that function in human cells are well known in the art and include viral systems. Generally, a promoter that functions in human cells is any DNA sequence capable of binding mammalian RNA polymerase and initiating downstream (3') transcription of a coding sequence into mRNA. A promoter contains a transcription initiation region, usually located proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A promoter will also usually contain an upstream promoter element (enhancer element), typically located within 100-200 base pairs upstream of the TATA box. The upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as promoters are promoters derived from mammalian viral genes, as these genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and CMV promoter.
[0237] If necessary, gene delivery agents such as integration sequences can also be used. Many integration sequences are known in the art (see, for example, Nunes-Duby et al., Nucleic Acids Res. 26:391-406, 1998; Sadwoski, J. Bacteriol., 165:341-357, 1986; Bestor, Cell, 122(3):322-325, 2005; Plasterk et al., TIG 15:326-332, 1999; Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These include recombinases and transposases. Examples include Cre (Sternberg and Hamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247, 543-545, 1974), FIp (Broach, et al., Cell, 29:227-234, 1982), R (Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (see, e.g., Groth et al., J. Mol. Biol., 335:667-678, 2004), sleeping beauty, transposases of the mariner family, and components for integrating viruses such as AAV, retrovirus, and antivirus, which have components providing viral integration, such as retroviral or lentiviral LTR sequences and AAV ITR sequences (Kootstra et al., J. Mol. Biol., 1999). (e.g., et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). Additionally, direct and targeted gene integration strategies may be used to insert nucleic acid sequences, including CRISPR / CAS9, zinc finger, TALEN, and meganuclease gene editing technologies.
[0238] Pharmaceutical Composition In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and the chimeric protein of any of the embodiments disclosed herein, the isolated polynucleotide of any of the embodiments disclosed herein, the mmRNA of any of the embodiments disclosed herein, the vector of any of the embodiments disclosed herein, or the host cell of any of the embodiments disclosed herein. In various embodiments, the pharmaceutical composition comprises the mmRNA of any of the embodiments disclosed herein.
[0239] Suitable pharmaceutical compositions are disclosed in U.S. Patent Nos. 8,710,200, 8,822,663, 8,999,380, 9,181,319, 9,254,311, 9,334,328, 9,464,124, 9,950,068, 10,626,400, 10,808,242, 11,020,477, U.S. Patent Application Publication Nos. 20220001026, 20210318817, 20210283262, 202003 Nos. 60481, 20200113844, 20200085758, 20170204152, 20190114089, 20190114090, 20180369374, 20180318385, 20190111003, and PCT International Application Nos. WO / 2017112943, WO2014 / 028429, and WO2017 / 201325, the entire contents of which are incorporated herein by reference.
[0240] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an isolated, modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence having at least about 95% sequence identity to an amino acid sequence selected from SEQ ID NOs: 80-93.
[0241] In various embodiments, the carrier is an mmRNA that includes a modification (e.g., an RNA element) that provides the desired translational regulatory activity. Such modifications are described in PCT Application No. PCT International Application Publication No. WO2018213789, the entire contents of which are incorporated herein by reference.
[0242] In some embodiments, the mmRNA further comprises a 3' untranslated region (UTR). In some embodiments, the 3' UTR comprises at least one microRNA-122 (miR-122) binding site. In some embodiments, the miR-122 binding site is a miR-122-3p binding site or a miR-122-5 binding site. In some embodiments, the mmRNA further comprises a spacer sequence between the open reading frame and the miRNA binding site. In some embodiments, the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.
[0243] In embodiments, the mmRNA further comprises a 5'UTR, which in embodiments possesses a Kozak sequence and / or forms a secondary structure that facilitates the binding of an elongation factor.
[0244] In embodiments, the mmRNA further comprises a 5' end cap, which in embodiments is Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, a 5' methyl G cap, or an analog thereof.
[0245] In any of the embodiments disclosed herein, the mmRNA may include one or more modifications. In any of the embodiments disclosed herein, the mmRNA may include at least one modification. In various embodiments, the modification is a nucleoside modification. In various embodiments, the modification is a base modification. In various embodiments, the modification is a sugar-phosphate backbone modification.
[0246] In embodiments, the modification is pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-Taurinomethyl-4-thio-uridine, 5-Methyl-uridine, 1-Methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-Thio-1-methyl-pseudouridine, 1-Methyl-1-deaza-pseudouridine, 2-Thio-1-methyl-1-deaza-pseudouridine, Dihydrouridine, Dihydropseudouridine, 2-Thio-dihydrouridine, 2-Thio-dihydropseudouridine, 2-Methoxyuridine, 2-Methoxy-4-thio-uridine, 4-Methoxy-pseudouridine, 4-Methoxy-2-thio- Pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine dine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deazaadenine, 7-deaza-8-azaadenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-Diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, and hydroxypropyl methyl esters. N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and combinations of any two or more thereof. In embodiments, the modification is pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), 2-thiouridine (s2U), 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2'-O-methyluridine, 1-methyl-pseudouridine (m1Ψ), 5-methoxy-uridine uridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyanouridine, 4'-thiouridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-diaminopurine (I), 1-methylinosine (m1I), wyosine (imG), me The modification is selected from chiruwaiosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, and combinations of any two or more thereof. In various embodiments, the modification is selected from pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.
[0247] In embodiments, the mmRNA comprises at least one N1-methylpseudouridine. In embodiments, the mmRNA is fully modified with chemically modified uridines. In embodiments, the mmRNA is fully modified with N1-methylpseudouridines.
[0248] In embodiments, the modification is pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, The uridine may be selected from 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine, or a combination of any two or more thereof.
[0249] In various embodiments, the modification is 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine Selected from cytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.
[0250] In embodiments, the modification is 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl) Selected from adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.
[0251] In various embodiments, the modification is selected from inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.
[0252] In embodiments, the modification is on the major groove face, hi embodiments, the hydrogen on C-5 of the uracil is replaced with a methyl or halo group.
[0253] In various embodiments, the mmRNA further comprises one or more modifications selected from 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine, 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, and 5'-O-(1-thiophosphate)-pseudouridine.
[0254] In various embodiments, the pharmaceutical composition is formulated as a lipid nanoparticle (LNP), lipoplex, or liposome. In various embodiments, the pharmaceutical composition is formulated as a lipid nanoparticle (LNP). In various embodiments, the mRNA described herein can be formulated in a cationic oil-in-water emulsion, where the emulsion particle comprises an oil core and a cationic lipid that can interact with the mRNA to immobilize the molecule in the emulsion particle. In various embodiments, the mRNA described herein can be formulated in a water-in-oil emulsion comprising a continuous hydrophobic phase in which a hydrophilic phase is dispersed. Exemplary emulsions can be made by the methods described in PCT International Application Publication Nos. WO2012006380 and WO201087791 (each of which is incorporated herein by reference in its entirety).
[0255] In some embodiments, the nucleic acids (e.g., mRNA) of the invention are formulated in lipid nanoparticles (LNPs), which typically comprise an ionizable cationic lipid, a non-cationic lipid, a sterol, and a PEG lipid component along with the nucleic acid cargo of interest. The lipid nanoparticles of the present invention can be prepared using the lipid nanoparticles described in, for example, PCT International Application Publication Nos. WO2021231854, WO2021050986, WO2021055833, WO2021213924, WO2021055849, WO2021214204, WO2021188969, WO2021055835, WO2020061284, WO2020061295, WO2017049245, WO2017031232, WO2017112865, WO2017218704 ...172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188969, WO20172188 and WO2017223135, WO2016118724, WO2015164674, WO2015038892, WO2014152211, and WO2013090648, the entire contents of each of which are incorporated herein by reference. The PEG lipid is selected from ionizable lipids (e.g., those known in the art, such as those described in U.S. Pat. No. 8,158,601, PCT International Application Publication No. WO2012099755, and PCT International Application Publication No. WO2015 / 130584, which are incorporated herein by reference in their entirety). The ionizable lipid can be selected from, but is not limited to, the ionizable lipids described in PCT International Application Publication No. WO2013086354 and PCT International Application Publication No. WO2013116126, the contents of each of which are incorporated herein by reference in their entirety. In various embodiments, the lipid can be a cleavable lipid, such as that described in PCT International Application Publication No. WO2012170889, which is incorporated herein by reference in its entirety.In various embodiments, the lipids can be synthesized by methods known in the art and / or described in International Publication No. WO2013086354, the contents of each of which are incorporated herein by reference in their entireties. In various embodiments, the LNP formulations described herein can further comprise a permeability-enhancing molecule. Non-limiting permeability-enhancing molecules are described in U.S. Publication No. US20050222064, the entire contents of which are incorporated herein by reference.
[0256] In various embodiments, the carrier is a lipid-like substance, a liposome, a lipoplex, a lipid nanoparticle, a polymer nanoparticle, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a complex. In various embodiments, the pharmaceutical composition is formulated as a lipid nanoparticle (LNP), a lipoplex, or a liposome. In various embodiments, the pharmaceutical composition is formulated as a lipid nanoparticle (LNP). In various embodiments, the lipid nanoparticles comprise a lipid selected from an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structural lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethylene glycol (PEG) lipid (e.g., PEG diacylglycerol (DAG), PEG dialkyloxypropyl (DAA), PEG phospholipid, PEG ceramide (Cer), or mixtures thereof, or PEG dilauryloxypropyl (C12, PEG dimyristyloxypropyl (C14), PEG dipalmityloxypropyl (C16), or PEG distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoylphosphatidylethanolamine (DOPE).
[0257] In various embodiments, the pharmaceutical composition is formulated as a lipid nanoparticle (LNP). In various embodiments, the LNP comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% structural lipid, and about 0.5-1.5% PEG lipid. In various embodiments, the LNP comprises a molar ratio of about 50% ionizable amino lipid, about 8-12% phospholipid, about 37-40% structural lipid, and about 1-2% PEG lipid. In various embodiments, the lipid nanoparticles comprise a lipid selected from an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structural lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethylene glycol (PEG) lipid (e.g., PEG diacylglycerol (DAG), PEG dialkyloxypropyl (DAA), PEG phospholipid, PEG ceramide (Cer), or mixtures thereof, or PEG dilauryloxypropyl (C12, PEG dimyristyloxypropyl (C14), PEG dipalmityloxypropyl (C16), or PEG distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoylphosphatidylethanolamine (DOPE).
[0258] In various embodiments, the lipid nanoparticles comprise (a) a cationic lipid comprising 50 mol% to 85 mol% of the total lipid present in the particle, (b) a non-cationic lipid comprising 13 mol% to 49.5 mol% of the total lipid present in the particle, and (c) a complex lipid that inhibits particle aggregation comprising 0.5 mol% to 2 mol% of the total lipid present in the particle. In various embodiments, the lipid nanoparticles comprise a lipid selected from SM-102, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200; cholesterol; and a PEG-lipid.
[0259] In any of the embodiments disclosed herein, the pharmaceutical composition is formulated for parenteral administration. In any of the embodiments disclosed herein, the pharmaceutical composition is formulated for topical administration.
[0260] In one aspect, the present disclosure provides a pharmaceutical composition comprising an mmRNA of any of the embodiments disclosed herein or an LNP comprising an mmRNA of any of the embodiments disclosed herein. In various embodiments, the pharmaceutical composition is formulated for parenteral administration.
[0261] In various embodiments, the pharmaceutical composition comprises a modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence having at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity to an amino acid sequence selected from SEQ ID NOs: 80-93. In various embodiments, the pharmaceutical composition is formulated as a LNP comprising an ionizable amino lipid, a phospholipid, a structural lipid, and a PEG-lipid.
[0262] In various embodiments, the pharmaceutical composition is formulated for parenteral administration. In various embodiments, the pharmaceutical composition is formulated for topical, cutaneous, intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial, or transdermal administration. In various embodiments, the pharmaceutical composition is formulated for topical administration.
[0263] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and the chimeric protein of any one of the embodiments disclosed herein, the isolated polynucleotide of any one of the embodiments disclosed herein, the vector of the embodiments disclosed herein, or the host cell of any of the embodiments disclosed herein. In various embodiments, the pharmaceutical composition comprises a nucleic acid, e.g., an mmRNA of any one of the embodiments disclosed herein.
[0264] In various embodiments, the lipid nanoparticles comprise a lipid selected from an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structural lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethylene glycol (PEG) lipid (e.g., PEG diacylglycerol (DAG), PEG dialkyloxypropyl (DAA), PEG phospholipid, PEG ceramide (Cer), or mixtures thereof, or PEG dilauryloxypropyl (C12, PEG dimyristyloxypropyl (C14), PEG dipalmityloxypropyl (C16), or PEG distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoylphosphatidylethanolamine (DOPE); and a nucleic acid, e.g., mRNA.
[0265] In various embodiments, the LNP comprises a molar ratio of about 20-60% ionizable amino lipid, about 5-25% phospholipid, about 25-55% structural lipid, and about 0.5-1.5% PEG lipid. In various embodiments, the ionizable amino lipid comprises the formula: [ka]
[0266] In various embodiments, the lipid nanoparticles comprise a lipid selected from an ionizable lipid; a structural lipid; cholesterol and polyethylene glycol (PEG) lipid; 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoylphosphatidylethanolamine (DOPE); and a nucleic acid (e.g., mmRNA). In various embodiments, the ionizable lipid is an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200. In various embodiments, the polyethylene glycol (PEG) lipid is selected from PEG diacylglycerol (DAG), PEG dialkyloxypropyl (DAA), PEG phospholipid, PEG ceramide (Cer), or mixtures thereof, or PEG dilauryloxypropyl (e.g., (C12), PEG dimyristyloxypropyl (C14), PEG dipalmityloxypropyl (C16), or PEG distearyloxypropyl (C18)).
[0267] In various embodiments, the isolated polynucleotide is or includes a conjugated polynucleotide sequence introduced into cells by various transfection methods, such as methods using lipid particles. In various embodiments, the composition including the gene transfer construct includes a delivery particle. In various embodiments, the delivery particle includes a lipid-based particle (e.g., lipid nanoparticle (LNP)), cationic lipid, or biodegradable polymer). Lipid nanoparticle (LNP) delivery of gene transfer constructs offers certain advantages, including transient, non-integrated expression to limit potential off-target events and immune responses, and efficient delivery with the ability to transport large cargoes. LNPs have been used to deliver small interfering RNA (siRNA) and mRNA, as well as CRISPR / Cas9 components to hepatocytes and the liver in vitro and in vivo. For example, U.S. Patent No. 10,195,291 describes the use of LNPs for the delivery of RNA interference (RNAi) therapeutic agents.
[0268] In various embodiments, compositions according to embodiments of the present disclosure are in the form of LNPs. In various embodiments, the LNPs are selected from the group consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), cationic cholesterol derivatives mixed with dimethylaminoethane-carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG). 2K), and 1,2-distearol-sn-glycerol-3 phosphocholine (DSPC).
[0269] In various embodiments, the composition may have various ratios of lipid and polymer, where the lipid may be selected from, for example, DOTAP, DC-Chol, PC, triolein, or DSPE-PEG, and the polymer may be, for example, PEI or polylactic-co-glycolic acid (PLGA). Additionally or alternatively, any other lipid and polymer may be used. In various embodiments, the lipid to polymer ratio is about 0.5:1, or about 1:1, or about 1:1.5, or about 1:2, or about 1:2.5, or about 1:3, or about 3:1, or about 2.5:1, or about 2:1, or about 1.5:1, or about 1:1, or about 1:0.5.
[0270] In various embodiments, the LNPs comprise cationic lipids, non-limiting examples of which include N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyloxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyloxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLin-DAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanediol (DOAP), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or its analogs, (3aR,5s,6aS)-N,N-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or its analogs, ethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen19-yl 4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-')amino)ethyl)(2hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (Tech G1), 1,2-dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), or mixtures thereof.
[0271] In various embodiments, the LNPs comprise one or more molecules selected from polyethyleneimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), which are suitable for hepatic delivery, and N-acetylgalactosamine (GalNAc). In various embodiments, the LNPs comprise a hepatotropic compound, such as those described in U.S. Patent No. 5,985,826, the entire contents of which are incorporated herein by reference. GalNAc is known to target the asialoglycoprotein receptor (ASGPR), which is expressed in mammalian hepatocytes. See Hu et al., Protein Pept Lett. 2014;21(10):1025-30.
[0272] In some examples, the isolated polynucleotides may be formulated or complexed with PEI or a derivative thereof, such as polyethyleneimine-polyethylene glycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethylene glycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives.
[0273] In various embodiments, the LNP is a conjugated lipid, non-limiting examples of which include polyethylene glycol (PEG)-lipids, including but not limited to PEG-diacylglycerol (DAG), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate can be, for example, PEG-dilauryloxypropyl (C12), PEG-dimyristyloxypropyl (C14), PEG-dipalmityloxypropyl (C16), or PEG-distearyloxypropyl (C18).
[0274] In various embodiments, the LNP formulation may further comprise a phosphate conjugate, which can prolong in vivo circulation time and / or increase targeted delivery of the nanoparticles. The phosphate conjugate can be made, for example, by methods described in PCT International Publication No. WO2013033438 or U.S. Publication No. US20130196948. The LNP formulation also contains a polymer conjugate (e.g., a water-soluble conjugate), for example, as described in U.S. Publication Nos. US20130059360, US20130196948, and US20130072709 (each of which is incorporated by reference in its entirety).
[0275] In various embodiments, the LNP formulation may include a carbohydrate carrier. Non-limiting examples of carbohydrate carriers include, but are not limited to, anhydrous-modified phytoglycogen or glycogen-type substances, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin, and anhydrous-modified phytoglycogen beta-dextrin (e.g., PCT International Publication No. WO2012109121, incorporated herein by reference in its entirety). In various embodiments, the LNP formulation may be coated with a surfactant or polymer to improve particle delivery. In some embodiments, the LNP may be coated with a hydrophilic coating, such as, but not limited to, a PEG coating and / or a coating with a neutral surface charge, as described in U.S. Publication No. US20130183244 (incorporated herein by reference in its entirety). In various embodiments, the LNP formulation may be engineered to alter the surface properties of the particle, thereby enabling the lipid nanoparticles to penetrate mucosal barriers. This is described in U.S. Patent No. 8,241,670 or PCT International Publication No. WO2013110028, each of which is incorporated herein by reference in its entirety.In various embodiments, mucus-penetrating LNP can be a hypotonic formulation comprising a mucosal permeation enhancing coating.The formulation can be hypotonic to the epithelium to be delivered.Non-limiting examples of hypotonic formulations are described, for example, in PCT International Publication No. WO2013110028, each of which is incorporated herein by reference in its entirety.
[0276] In various embodiments, the mmRNA described herein are formulated as solid lipid nanoparticles (SLNs), which can be spherical with an average diameter of 10-1000 nm. SLNs possess a solid lipid core matrix that can solubilize lipophilic molecules and can be stabilized with surfactants and / or emulsifiers. Exemplary SLNs can be those described in PCT International Publication No. WO2013105101, the entire contents of which are incorporated herein by reference.
[0277] In various embodiments, nanoparticles are particles having a diameter of less than about 1000 nm. In various embodiments, nanoparticles of the present disclosure have a maximum dimension (e.g., diameter) of about 500 nm or less, or about 400 nm or less, or about 300 nm or less, or about 200 nm or less, or about 100 nm or less. In various embodiments, nanoparticles of the present disclosure have a maximum dimension in the range of about 50 nm to about 150 nm, or about 70 nm to about 130 nm, or about 80 nm to about 120 nm, or about 90 nm to about 110 nm. In various embodiments, nanoparticles of the present disclosure have a maximum dimension (e.g., diameter) of about 100 nm.
[0278] In various embodiments, therapeutic nanoparticles comprising chimeric proteins or mRNA can be formulated for sustained release, and as used herein, sustained release refers to a pharmaceutical composition or compound adapted for a release rate over a specific period of time. In various embodiments, the period of time includes, but is not limited to, hours, days, weeks, months, and years. As a non-limiting example, sustained release nanoparticles of mRNA described herein can be formulated as disclosed in PCT International Publication No. WO2010075072, and U.S. Publication Nos. US20100216804, US20110217377, US20120201859, and US20130150295 (each of which is incorporated herein by reference in its entirety).
[0279] In various embodiments, the chimeric protein, or isolated polynucleotide or mmRNA (and / or additional agent) is included in various formulations. Any chimeric protein, or isolated polynucleotide or mmRNA (and / or additional agent) described herein may be in the form of a solution, suspension, emulsion, infusion, tablet, pill, pellet, capsule, liquid-containing capsule, powder, sustained-release formulation, suppository, emulsion, aerosol, spray, suspension, or other form suitable for use. DNA or RNA constructs encoding the protein sequence may also be used. In various embodiments, the composition is in the form of a capsule (see, e.g., U.S. Pat. No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference.
[0280] In embodiments, the present disclosure provides an expression vector comprising a nucleic acid encoding a chimeric protein described herein. In embodiments, the expression vector comprises DNA or RNA. In embodiments, the expression vector is a mammalian expression vector.
[0281] Both prokaryotic and eukaryotic vectors can be used to express the chimeric proteins. Prokaryotic vectors include constructs based on E. coli sequences (see, e.g., Makrides, Microbiol Rev 1996, 60:512-538). Non-limiting examples of regulatory regions that can be used for expression in E. coli include lac, trp, lpp, phoA, recA, tac, T3, T7, and λP. LExamples of prokaryotic expression vectors include the λgt vector series, such as λgt11 (Huynh et al., in "DNA Cloning Techniques, Vol. I: A Practical Approach," 1984, (D. Glover, ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series (Studier et al., Methods Enzymol 1990, 185:60-89). However, prokaryotic host-vector systems cannot perform many of the post-translational processes of mammalian cells. Therefore, eukaryotic host-vector systems may be particularly useful. Various regulatory regions can be used to express chimeric proteins in mammalian host cells. For example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate-early promoter, and the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter can be used. Inducible promoters that may be useful in mammalian cells include, but are not limited to, promoters associated with the metallothionein II gene, mouse mammary tumor virus glucocorticoid-responsive long terminal repeat (MMTV-LTR), β-interferon gene, and hsp70 gene (see, for example, Williams et al., Cancer Res 1989, 49:2735-42, and Taylor et al., Mol Cell Biol 1990, 10:165-75). Heat shock promoters or stress promoters may also be advantageous for driving the expression of chimeric proteins in recombinant host cells.
[0282] In various embodiments, the expression vectors of the present disclosure comprise a nucleic acid encoding a chimeric protein or its complement (and / or an additional agent) operably linked to an expression control region or its complement that is functional in mammalian cells and capable of driving expression of the nucleic acid encoding the operably linked blocking and / or stimulating factor such that the blocking and / or stimulating factor is produced in human cells transformed with the expression vector.
[0283] Expression control regions are regulatory polynucleotides (sometimes referred to herein as elements), such as promoters and enhancers, that affect the expression of an operably linked nucleic acid. The expression control regions of the expression vectors of the present disclosure are capable of expressing an operably linked encoding nucleic acid in a human cell. In various embodiments, the cell is an epithelial cell. In various embodiments, the cell is located within or near a pathological lesion caused by or associated with inflammation of the integumentary system. In various embodiments, the cell is a non-tumor cell. In various embodiments, the expression control region confers regulatable expression to the operably linked nucleic acid. A signal (sometimes referred to as a stimulus) can increase or decrease the expression of a nucleic acid operably linked to such an expression control region. Such expression control regions that increase expression in response to a signal are often referred to as inducible. Such expression control regions that decrease expression in response to a signal are often referred to as repressible. Typically, the amount of increase or decrease conferred by such an element is proportional to the amount of signal present; the greater the amount of signal, the greater the increase or decrease in expression.
[0284] In various embodiments, the present disclosure contemplates the use of inducible promoters that can result in transient high levels of expression in response to a cue. For example, when cells are near a lesion caused by or associated with inflammation of the integumentary system, transformed with an expression vector for a chimeric protein (and / or additional agent) containing such expression control sequences can be induced to transiently produce high levels of the agent by exposing the transformed cells to the appropriate cue. Exemplary inducible expression control regions include those containing inducible promoters that are stimulated by a cue, such as a small molecule compound. Specific examples can be found, for example, in U.S. Patent Nos. 5,989,910, 5,935,934, 6,015,709, and 6,004,941, each of which is incorporated herein by reference in its entirety.
[0285] Expression control regions and locus control regions include full-length promoter sequences, such as native promoter and enhancer elements, as well as subsequences or polynucleotide variants that retain all or a portion of the full-length or non-variant function. As used herein, the term "functional" and grammatical variations thereof, when used in reference to a nucleic acid sequence, subsequence, or fragment, means that the sequence has one or more functions of the native nucleic acid sequence (e.g., the non-variant or unmodified sequence).
[0286] As used herein, "operably linked" refers to the physical juxtaposition of the described components so as to allow them to function in their intended manner. In the example of an expression control element operably linked to a nucleic acid, this relationship is such that the control element regulates expression of the nucleic acid. Typically, an expression control region that regulates transcription is juxtaposed near the 5' end (i.e., "upstream") of the transcribed nucleic acid. An expression control region can also be located at the 3' end (i.e., "downstream") of the transcribed sequence or within the transcript (e.g., within an intron). An expression control element can be located at a distance from the transcribed sequence (e.g., 100-500, 500-1000, 2000-5000, or more nucleotides from the nucleic acid). A particular example of an expression control element is a promoter, which is usually located 5' to the transcribed sequence. Another example of an expression control element is an enhancer, which can be located 5' or 3' to the transcribed sequence or within the transcribed sequence.
[0287] Expression systems that function in human cells are well known in the art and include viral systems. Generally, a promoter that functions in human cells is any DNA sequence capable of binding mammalian RNA polymerase and initiating downstream (3') transcription of a coding sequence into mRNA. A promoter usually contains a transcription initiation region, usually located proximal to the 5' end of the coding sequence, and a TATA box, typically located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A promoter will also typically contain an upstream promoter element (enhancer element), typically located within 100-200 base pairs upstream of the TATA box. The upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as promoters are promoters derived from mammalian viral genes, as these genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and CMV promoter. Examples of promoters expressed in the integumentary system include the keratin 5 (K5) promoter, keratin 6 (K6) promoter, keratin 14 (K14) promoter, keratin 16 (K16) promoter, α1(I) collagen promoter, filaggrin promoter, loricrin promoter, involucrin promoter, tyrosinase promoter, and αV integrin promoter.
[0288] Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' of the translation stop codon and thus, together with the promoter element, flank the coding sequence. The 3' end of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40. Introns may also be included in the expression construct.
[0289] Various techniques are available for introducing nucleic acids into living cells. Suitable techniques for in vitro nucleic acid transfer into mammalian cells include the use of liposomes, electroporation, microinjection, cell fusion, polymer-based systems, DEAE-dextran, viral transduction, calcium phosphate precipitation, and the like. For in vivo gene transfer, numerous techniques and reagents may also be used, including liposomes, natural polymer-based delivery vehicles such as chitosan and gelatin. Viral vectors are also suitable for in vivo transduction. In some situations, it may be desirable to provide a targeting agent, such as an antibody or ligand specific for a cell surface membrane protein, from cells located within or near a pathological lesion caused by or associated with inflammation in the integumentary system. When liposomes are used, proteins that bind to cell surface membrane proteins associated with endocytosis may be used to target and / or promote uptake of, for example, capsid proteins or fragments thereof with tropism for specific cell types, antibodies for proteins that undergo internalization in the circulation, proteins that target intracellular localization and enhance intracellular half-life, and / or the like. The technique of receptor-mediated endocytosis is described, for example, in Wu et al., J. Biol. Chem. 262, 4429-4432 (1987), and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990).
[0290] If necessary, gene delivery agents such as integration sequences can also be used. Numerous integration sequences are known in the art (see, for example, Nunes-Duby et al., Nucleic Acids Res. 26:391-406, 1998; Sadwoski, J. Bacteriol., 165:341-357, 1986; Bestor, Cell, 122(3):322-325, 2005; Plasterk et al., TIG 15:326-332, 1999; Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These include recombinases and transposases. Examples include Cre (Sternberg and Hamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247, 543-545, 1974), FIp (Broach, et al., Cell, 29:227-234, 1982), R (Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (see, e.g., Groth et al., J. Mol. Biol., 335:667-678, 2004), sleeping beauty, and transposases of the mariner family (Plasterk et al., J. Mol. Biol., 335:667-678, 2004). al., supra), and components for integrating viruses such as AAV, retroviruses, and antiviruses, which have components that provide viral integration, such as retroviral or lentiviral LTR sequences and AAV ITR sequences (Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). Additionally, direct and targeted gene integration strategies can be used to insert nucleic acid sequences encoding chimeric proteins, including CRISPR / CAS9, zinc finger, TALEN, and meganuclease gene editing technologies.
[0291] In one aspect, the present disclosure provides an expression vector for expression of the chimeric protein (and / or additional agent) that is a viral vector. Many viral vectors useful for gene therapy are known (see, e.g., Lundstrom, Trends Biotechnol., 21:1 17, 122, 2003). Exemplary viral vectors include those selected from antiviruses (LV), retroviruses (RV), adenoviruses (AV), adeno-associated viruses (AAV), and alphaviruses, although other viral vectors may also be used. For in vivo use, viral vectors that do not integrate into the host genome, such as alphaviruses and adenoviruses, are preferred for use. Exemplary types of alphaviruses include Sindbis virus, Venezuelan equine encephalitis (VEE) virus, and Semliki Forest virus (SFV). For in vitro use, viral vectors that integrate into the host genome, such as retroviruses, AAV, and antiviruses, are preferred. In various embodiments, the present disclosure provides a method of transducing human cells in vivo, comprising contacting cells located within or near a pathological lesion caused by or associated with inflammation of the integumentary system with a viral vector of the present disclosure. In embodiments, the present disclosure provides a host cell comprising an expression vector comprising a chimeric protein described herein. In embodiments, the present disclosure provides a host cell comprising RNA (e.g., but not limited to, mmRNA) encoding the chimeric protein of any of the embodiments disclosed herein.
[0292] To produce the chimeric proteins of the invention, the expression vectors may be introduced into host cells. The cells may be cultured or genetically engineered, for example, in vitro. Useful mammalian host cells include, but are not limited to, cells derived from humans, monkeys, and rodents (see, e.g., Kriegler, in "Gene Transfer and Expression: A Laboratory Manual," 1990, New York, Freeman & Co.). These include SV40-transformed monkey kidney cell lines (e.g., COS-7, ATCC CRL1651); human embryonic kidney lines (e.g., 293, 293-EBNA, or 293 cells subcloned for growth in suspension culture, Graham et al., J Gen Virol 1977, 36:59); baby hamster kidney cells (e.g., BHK, ATCC CCL10); Chinese hamster ovary cells-DHFR (e.g., CHO, Urlaub and Chasin, Proc Natl Acad Sci USA 1980, 77:4216), DG44 CHO cells, CHO-K1 cells, mouse Sertoli cells (Mather, Biol Reprod 1980, 23:243-251); mouse fibroblasts (e.g., NIH-3T3), monkey kidney cells (e.g., CV1 ATCC CCL70); African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical cancer cells (e.g., HELA, ATCC CCL2); canine kidney cells (e.g., MDCK, ATCC CCL34); buffalo rat liver cells (e.g., BRL 3A, ATCC CRL1442), human lung cells (e.g., W138, ATCC CCL75); human liver cells (e.g., Hep G2, HB8065); and mouse mammary tumor cells (e.g., MMT060562, ATCC CCL51).Exemplary cell types for expressing the chimeric proteins described herein include the mouse fibroblast cell line, NIH3T3, the mouse Lewis lung carcinoma cell line, LLC, the mouse mastocytoma cell line, P815, the mouse lymphoma cell line, EL4 and its ovalbumin transfectant, E.G7, the mouse melanoma cell line, B16F10, the mouse fibrosarcoma cell line, MC57, and the human small cell lung carcinoma cell lines, SCLC#2 and SCLC#7. Host cells can be obtained from normal or diseased subjects, including healthy humans, patients with integumentary inflammation, and patients with infectious diseases, from commercial laboratory deposits, public culture collections such as the American Type Culture Collection, or commercial suppliers.
[0293] Cells that can be used to produce the chimeric proteins of the invention in vitro, ex vivo, and / or in vivo include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells, e.g., T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, particularly hematopoietic stem or progenitor cells (e.g., obtained from bone marrow), umbilical cord blood, peripheral blood, fetal liver, etc. The choice of cell type will depend on the type of disease or disorder caused by or associated with inflammation of the integumentary system being treated or prevented and can be determined by one of skill in the art.
[0294] If necessary, the formulation containing the chimeric protein or isolated polynucleotide or mmRNA (and / or additional agent) may also include a solubilizing agent. The agent may also be delivered using a suitable vehicle or delivery device known in the art. The combination therapies outlined herein may be co-delivered in a single delivery vehicle or device. The composition for administration may optionally include a local anesthetic, such as lignocaine, to alleviate pain at the site of injection.
[0295] Formulations comprising the chimeric protein of the present disclosure (and / or additional agents) may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agent into association with the carrier, which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with liquid carriers, finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired formulation (e.g., wet or dry granulation, powder blending, etc., followed by tableting using conventional methods known in the art).
[0296] In various embodiments, any chimeric protein, or isolated polynucleotide or mRNA (and / or additional agents) described herein are formulated in accordance with routine procedures into compositions compatible with the modes of administration described herein.
[0297] Any chimeric protein or isolated polynucleotide or mmRNA (and / or additional agent) described herein may be administered orally. Such chimeric proteins (and / or additional agents) may also be administered by other convenient routes, such as intravenous infusion or bolus injection, absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa, etc.), or may be administered together with another biologically active agent. Administration may be systemic or local. Various delivery systems, such as encapsulation in liposomes, microparticles, microcapsules, capsules, etc., are known and can be used for administration.
[0298] The dosage and administration schedule of any chimeric protein, or isolated polynucleotide or mmRNA (and / or additional agent) described herein can depend on various parameters, including, but not limited to, the disease being treated, the general health of the subject, and the discretion of the administering physician. Any chimeric protein described herein can be administered to a subject in need thereof prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), simultaneously with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the additional agent. In various embodiments, any chimeric protein described herein and the additional agent are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 to 2 hours apart, 2 to 3 hours apart, 3 to 4 hours apart, 4 to 5 hours apart, 5 to 6 hours apart, 6 to 7 hours apart, 7 to 8 hours apart, 8 to 9 hours apart, 9 to 10 hours apart, 10 to 11 hours apart, 11 to 12 hours apart, 1 day apart, 2 days apart, 3 days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2 weeks apart, 3 weeks apart, or 4 weeks apart.
[0299] The dosage of any chimeric protein, or isolated polynucleotide or mmRNA (and / or additional agent) described herein may depend on several factors, including the severity of the condition, whether the condition is being treated or prevented, and the age, weight, and health of the subject being treated. Furthermore, pharmacogenomic (the effect of genotype on therapeutic pharmacokinetic, pharmacodynamic, or efficacy profile) information about a particular subject may influence the dosage used. Furthermore, the exact individual dosage may be adjusted slightly depending on a variety of factors, including the specific combination of agents administered, the duration of administration, the route of administration, the nature of the formulation, the excretion rate, the specific disease being treated, the severity of the disorder, and the anatomical location of the disorder. Some variation in dosage may be expected.
[0300] In various embodiments, delivery can be in a vesicle, particularly a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989)).
[0301] Any chimeric protein, or isolated polynucleotide or mRNA (and / or additional agents) described herein can be administered by controlled-release or sustained-release means or by delivery devices known to those of skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos. 3,845,770, 3,916,899, 3,536,809, 3,598,123, 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,556, each of which is incorporated herein by reference in its entirety. Such dosage forms can be useful for providing controlled or sustained release of one or more active ingredients, for example, using hydropropylmethylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof to provide desired release profiles at various rates. Controlled or sustained release of active ingredients can be stimulated by various conditions, including, but not limited to, changes in pH, temperature, stimulation with light of an appropriate wavelength, enzyme concentration or availability, water concentration or availability, or other physiological conditions or compounds.
[0302] In various embodiments, polymeric materials may be used (see, Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).
[0303] In various embodiments, controlled-release systems can be placed in proximity to the target area to be treated, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, Science 249:1527-1533 may also be used.
[0304] Administration of any chimeric protein, or isolated polynucleotide or mmRNA (and / or additional agents) described herein can, independently, be 1 to 4 times daily, or 1 to 4 times monthly, or 1 to 6 times per year, or once every 2, 3, 4, or 5 years. Administration can be daily or for a period of 1, 2, 3, 6 months, 1, 2, 3 years, or even for the lifetime of the subject.
[0305] Dosage regimens utilizing any of the chimeric proteins or isolated polynucleotides or mmRNAs described herein (and / or additional agents) can be selected depending on a variety of factors, including the type, species, age, weight, sex, and medical condition of the subject; the severity of the condition being treated; the route of administration; the subject's renal or hepatic function; the individual's pharmacogenomic makeup; and the particular compound of the present disclosure being used. Any of the chimeric proteins (and / or additional agents) described herein can also be administered once daily, or the total daily dose can be administered in divided doses two, three, or four times daily. Furthermore, any of the chimeric proteins (and / or additional agents) described herein can also be administered continuously rather than intermittently throughout the dosing regimen.
[0306] In one aspect, the present disclosure provides a host comprising a polynucleotide of any of the embodiments disclosed herein.
[0307] In one aspect, the present disclosure provides a host cell comprising a vector of any of the embodiments disclosed herein. In one aspect, the present disclosure provides a host cell comprising an RNA (e.g., but not limited to, an mmRNA) encoding a chimeric protein of any of the embodiments disclosed herein.
[0308] Diseases / Disorders that can be Treated with the Chimeric Proteins or Nucleic Acids Encoding the Chimeric Proteins of the Disclosure In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, modified mRNA (mmRNA)) encoding the chimeric proteins disclosed herein are suitable for treating or preventing autoimmune and / or allergic diseases. In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing a disease or disorder selected from rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Behcet's disease, sarcoidosis, wound ulcers, vasculitis, and pyoderma gangrenosum.
[0309] In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing inflammation mediated by macrophages, monocytes, dendritic cells, and / or T cells. In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing inflammation mediated by cytokines, e.g., TNFα, IL-17, and / or IL-23. In various embodiments, the inflammation is caused by or associated with a disease or disorder of the integumentary system. In various embodiments, the inflammation is caused by or associated with a disease or disorder of the skin.
[0310] In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing a disease in which TNFα activity is detrimental in a subject, including, but not limited to, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis (JIA), ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), hepatitis C, endometriosis, asthma, cachexia, psoriasis, or atopic dermatitis, or other inflammatory or autoimmune-related diseases, disorders, or conditions. Additional diseases that can be treated with the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are described in International Patent Application Publication Nos. WO2000 / 062790, WO2001 / 062272, and U.S. Patent Nos. 8,772,458, 7,700,318, and U.S. Patent Publication Nos. 2019 / 0135929 and 2021 / 0177983, the entire contents of which are incorporated by reference herein in their entireties.
[0311] In various embodiments, the chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mmRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing a skin disease or disorder selected from psoriasis, pemphigus vulgaris, scleroderma, atopic dermatitis, sarcoidosis, erythema nodosum, hidradenitis suppurativa, lichen planus, Sweet's syndrome, vitiligo, chronic paronychia, eczema, seborrheic dermatitis, and / or urticaria.
[0312] The chimeric proteins disclosed herein or nucleic acids (e.g., but not limited to, mRNA) encoding the chimeric proteins disclosed herein are suitable for treating or preventing psoriasis (e.g., but not limited to, plaque psoriasis and psoriatic arthritis).
[0313] Psoriasis is a chronic inflammatory skin disease unique to humans. It is characterized by dense infiltration of T cells and cells of the innate immune system, including neutrophils, dendritic cells, macrophages, and NK cells, in psoriatic skin lesions. Psoriasis is also characterized by hyperproliferation and abnormal differentiation of dermal epithelial cells (e.g., keratinocytes), causing significant thickening of the epidermis. A dramatic increase in the number and size of blood vessels just below the epidermis is observed. Abscesses composed of neutrophils form within the epidermis, causing redness, thickening, and flaking of the skin. The mechanisms driving hyperproliferation of keratinocytes and activation of macrophages in the skin have not yet been fully elucidated. While symptoms (e.g., skin lesions) can be treated in the short term, psoriasis is a chronic, lifelong disease for many patients because symptoms recur when treatment is discontinued.
[0314] Treatment method In one aspect, the present disclosure relates to a method for treating a subject with an autoimmune condition or an inflammatory disorder, comprising administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of tumor necrosis factor (TNF) receptor 2 (TNFR2), or a variant or fragment thereof capable of binding to a TNFR2 ligand, and (c) is a first domain comprising CLEC7a or a variant or fragment thereof capable of binding to a CLEC7a ligand, DC-SIGN (CD209), or a DC-SIGN (CD209) ligand. and (b) a second domain comprising an extracellular domain selected from the group consisting of Dectin 2 (CLEC6A) or a variant or fragment thereof capable of binding to a Dectin 2 (CLEC6A) ligand, Langerin (CD207, CLC4K) or a variant or fragment thereof capable of binding to a Langerin (CD207, CLC4K) ligand, and CD69 or a variant or fragment thereof capable of binding to a CD69 ligand. (b) is a linker flanking the first and second domains, the linker comprising at least one cysteine residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain. In some embodiments, the TNFR2 ligand is TNFα. In some embodiments, the CLEC7a ligand is a β-1,3-linked and / or β-1,6-linked glucan. In embodiments, the DC-SIGN (CD209) ligand is intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3). In embodiments, the Dectin 2 (CLEC6A) ligand is alpha-mannan. In embodiments, the Langerin (CD207, CLC4K) ligand is a sulfated glycan, a mannosylated glycan, keratan sulfate (KS) and / or beta-glucan. In embodiments, the CD69 ligand is galectin 1 (Gal-1) or the S100A8 / S100A9 complex. In embodiments, the isolated polynucleotide is or comprises mRNA. In embodiments, the isolated polynucleotide is or comprises mRNA modified according to any of the embodiments disclosed herein.
[0315] In one aspect, the disclosure relates to a method of inducing rapid and sustained immunosuppression in a subject, comprising administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising the extracellular domain of tumor necrosis factor (TNF) receptor 2 (TNFR2), or a variant or fragment thereof capable of binding to a TNFR2 ligand, and (c) is a first domain comprising CLEC7a or a variant or fragment thereof capable of binding to a CLEC7a ligand, DC-SIGN (CD209), or a variant or fragment thereof capable of binding to a DC-SIGN (CD209) ligand. and (b) a second domain comprising an extracellular domain selected from the group consisting of Dectin 2 (CLEC6A) or a variant or fragment thereof capable of binding to a Dectin 2 (CLEC6A) ligand, Langerin (CD207...
Claims
1. A chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, (a) a first domain comprising a portion of the TNF receptor (TNFR2) capable of binding to TNFα and / or oligomerizing with a cellular TNF receptor; (b) is a linker flanking the first and second domains, optionally comprising a hinge-CH2-CH3 Fc domain; (c) is a second domain comprising a portion of a C-type lectin receptor (CLR) capable of binding to a ligand.
2. The chimeric protein of claim 1 , wherein the portion of TNFR2 comprises the extracellular domain of TNFR2 or a fragment thereof.
3. The chimeric protein of claim 1 or claim 2, wherein the portion of TNFR2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:
57.
4. 4. The chimeric protein of claim 1, wherein the CLR is selected from C-type lectin domain-containing 7A (Clec7A), Langerin, dendritic cell-specific intercellular adhesion molecule 3-binding nonintegrin (DC-SIGN), and dendritic cell-associated C-type lectin 2 (Dectin 2).
5. The chimeric protein of any one of claims 1 to 4, wherein the second domain comprises a portion of Clec7a.
6. The chimeric protein of claim 5 , wherein the portion of Clec7a comprises an extracellular domain of Clec7a or a fragment thereof capable of binding to β-1,3-linked and / or β-1,6-linked glucans.
7. 7. The chimeric protein of claim 5 or claim 6, wherein the portion of Clec7a comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:
59.
8. The chimeric protein comprises: an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of Clec7a comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58 or SEQ ID NO:59; The chimeric protein of any one of claims 5 to 7, comprising a linker adjacent to the extracellular domain.
9. The chimeric protein of any one of claims 1 to 4, wherein the second domain comprises a portion of Langerin.
10. The chimeric protein of claim 9 , wherein the portion of Langerin comprises the extracellular domain of Langerin or a fragment thereof capable of binding to sulfated glycans, mannosylated glycans, keratan sulfate (KS) and / or beta-glucans.
11. The chimeric protein of claim 9 or claim 10, wherein the portion of Langerin comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:
61.
12. The chimeric protein comprises: an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of Langerin comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:60 or SEQ ID NO:61; A chimeric protein according to any one of claims 9 to 11, comprising a linker adjacent to the extracellular domain.
13. The chimeric protein of any one of claims 1 to 4, wherein the second domain comprises a portion of DC-SIGN.
14. The chimeric protein of claim 13, wherein the portion of DC-SIGN comprises an extracellular domain of DC-SIGN or a fragment thereof capable of binding to intercellular adhesion molecule 2 (ICAM2) and / or intercellular adhesion molecule 3 (ICAM3).
15. The chimeric protein of claim 13 or claim 14, wherein the portion of DC-SIGN comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:
63.
16. The chimeric protein comprises: an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; a portion of DC-SIGN comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:62 or SEQ ID NO:63; A chimeric protein according to any one of claims 13 to 15, comprising a linker adjacent to the extracellular domain.
17. The chimeric protein of any one of claims 1 to 4, wherein the second domain comprises a portion of Dectin-2.
18. The chimeric protein of claim 17, wherein the portion of Dectin-2 comprises the extracellular domain of Dectin-2, or a fragment thereof capable of binding to alpha-mannan.
19. The chimeric protein of claim 17 or claim 18, wherein the portion of Dectin 2 comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:
65.
20. The chimeric protein comprises: an extracellular domain of TNFR2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57; A portion of Dectin 2 comprising an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:65; A chimeric protein according to any one of claims 17 to 19, comprising a linker adjacent to the extracellular domain.
21. The chimeric protein of any one of claims 1 to 20, wherein the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4, such as human IgG1 or IgG4.
22. 22. The chimeric protein of claim 21, wherein the hinge-CH2-CH3 Fc domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:
73.
23. The chimeric protein of claim 21 or claim 22, wherein the linker further comprises one or more bond linkers, such bond linkers being independently selected from SEQ ID NOs: 4-50.
24. 24. The chimeric protein of any one of claims 21 to 23, wherein the linker comprises two or more linked linkers, each linked linker independently selected from SEQ ID NO:4 to SEQ ID NO:50, one linked linker being N-terminal to the hinge-CH2-CH3 Fc domain and another linked linker being C-terminal to the hinge-CH2-CH3 Fc domain.
25. An isolated polynucleotide encoding the chimeric protein of any one of claims 1 to 24.
26. 26. The isolated polynucleotide of claim 25, wherein the polynucleotide is or comprises mRNA or modified mRNA (mmRNA).
27. The isolated polynucleotide of claim 25 or claim 26, wherein the polynucleotide is or comprises mmRNA.
28. 28. The isolated polynucleotide of claim 27, wherein the mmRNA comprises one or more nucleoside modifications.
29. The nucleoside modifications include pyridin-4-one ribonucleosides, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio- Pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine zebularine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deazaadenine, 7-deaza-8-azaadenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-Diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wyobutosine, 7-deaza-guanosine, 7-deaza-8-aza 29. The isolated polynucleotide of claim 28, wherein the polynucleotide is selected from N-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and combinations thereof.
30. 30. The isolated polynucleotide of any one of claims 27 to 29, wherein the mmRNA further comprises a 5' cap and / or a polyA tail.
31. 26. The isolated polynucleotide of claim 25, wherein the polynucleotide is DNA.
32. 32. The isolated polynucleotide of claim 31 , wherein the polynucleotide comprises a skin-specific regulatory element.
33. 33. The isolated polynucleotide of claim 32, wherein the skin-specific regulatory element is a skin-specific promoter selected from the group consisting of a keratin 5 (K5) promoter, a keratin 6 (K6) promoter, a keratin 14 (K14) promoter, a keratin 16 (K16) promoter, an alpha-1 (I) collagen promoter, a filaggrin promoter, a loricrin promoter, an involucrin promoter, a tyrosinase promoter, and an alphaV integrin promoter.
34. 27. The isolated polynucleotide of claim 25 or claim 26, wherein the polynucleotide is or comprises mRNA.
35. A vector comprising the polynucleotide according to any one of claims 31 to 34.
36. A host cell comprising a polynucleotide according to any one of claims 25 to 34.
37. A host cell comprising the vector of claim 35.
38. 38. A pharmaceutical composition comprising a pharma- ceutically acceptable excipient or carrier and the chimeric protein of any one of claims 1-24, the isolated polynucleotide of any one of claims 25-34, the mmRNA of any one of claims 26-30, the vector of claim 35, or the host cell of claim 37.
39. The pharmaceutical composition of claim 38, wherein the pharmaceutical composition comprises the mmRNA of any one of claims 26 to 30.
40. 40. The pharmaceutical composition of claim 38 or claim 39, wherein the carrier is a lipid mimetic, a liposome, a lipoplex, a lipid nanoparticle, a polymeric nanoparticle, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a complex.
41. The pharmaceutical composition according to any one of claims 38 to 40, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP), a lipoplex, or a liposome.
42. 42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is formulated as a lipid nanoparticle (LNP).
43. The lipid nanoparticles may comprise an ionizable lipid (e.g., an ionizable cationic lipid selected from DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200); a structured lipid (e.g., distearoylphosphatidylcholine (DSPC)); cholesterol, and a polyethylene glycol (PEG) lipid (e.g., PEG diacylglycerol (DAG), PEG dialkyloxypropyl (DAA)). , PEG phospholipid, PEG ceramide (Cer), or mixtures thereof, or PEG dilauryloxypropyl (C12, PEG dimyristyloxypropyl (C14), PEG dipalmityloxypropyl (C16), or PEG distearyloxypropyl (C18)); 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoylphosphatidylethanolamine (DOPE).
44. The lipid nanoparticles comprise (a) a cationic lipid comprising 50 mol% to 85 mol% of the total lipid present in the particle, (b) a non-cationic lipid comprising 13 mol% to 49.5 mol% of the total lipid present in the particle, and (c) a complex lipid that inhibits particle aggregation comprising 0.5 mol% to 2 mol% of the total lipid present in the particle. The pharmaceutical composition of claim 42 or 43.
45. 45. The pharmaceutical composition of any one of claims 42 to 44, wherein the lipid nanoparticles comprise a lipid selected from SM-102, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5 and C12-200; cholesterol; and PEG lipids.
46. The pharmaceutical composition of any one of claims 38 to 45, wherein the pharmaceutical composition is formulated for parenteral administration.
47. 46. The pharmaceutical composition of any one of claims 38 to 45, wherein the pharmaceutical composition is formulated for topical, dermal, intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial or transdermal administration.
48. The pharmaceutical composition of any one of claims 38 to 45, wherein the pharmaceutical composition is formulated for topical administration.
49. 37. A method of treating or preventing inflammation of the integumentary system, the method comprising administering to a subject a chimeric protein of any one of claims 1-24, an isolated polynucleotide of any one of claims 25-34, a mmRNA of any one of claims 26-30, a vector of claim 35, or a host cell of claim 37.
50. A method for treating or preventing inflammation of the integumentary system, comprising administering to a subject a pharmaceutical composition according to any one of claims 38 to 48.
51. 51. The method of claim 49 or claim 50, wherein the inflammation is caused by or associated with a disease or disorder of the integumentary system.
52. 52. The method of any one of claims 49 to 51, wherein the inflammation is caused by or associated with a skin disease or disorder.
53. 53. The method of claim 52, wherein the skin disease or disorder is psoriasis, pemphigus vulgaris, scleroderma, atopic dermatitis, sarcoidosis, erythema nodosum, hidradenitis suppurativa, lichen planus, Sweet's syndrome, vitiligo, chronic paronychia, eczema, seborrheic dermatitis, and / or urticaria.
54. 54. The method of claim 52 or claim 53, wherein the skin disease or disorder is psoriasis.
55. 55. The method of claim 54, wherein the psoriasis is plaque psoriasis.
56. 55. The method of claim 54, wherein the psoriasis is psoriatic arthritis.
57. 57. The method of any one of claims 49 to 56, wherein the inflammation is mediated by macrophages and / or dendritic cells.
58. The treatment the infiltration level of T cells, neutrophils, dendritic cells, macrophages and / or NK cells in the inflamed tissue compared to the infiltration level of T cells, neutrophils, dendritic cells, macrophages and / or NK cells before said treatment; and / or 58. The method of any one of claims 49 to 57, wherein the levels of TNFα, IL-17 and / or IL-23 in the inflamed tissue are reduced compared to the levels of TNFα, IL-17 and / or IL-23 before the treatment.
59. 59. The method of any one of claims 54 to 58, wherein said treatment results in a reduction in redness, thickening and peeling of the skin compared to the reduction in redness, thickening and peeling of the skin prior to said treatment.
60. 60. The method of any one of claims 54 to 59, further comprising administering to the subject an anti-inflammatory drug.
61. 61. The method of claim 60, wherein the anti-inflammatory drug is a nonsteroidal anti-inflammatory drug or a corticosteroid.
62. 62. The method of claim 60 or claim 61, wherein the pharmaceutical composition and the anti-inflammatory agent are provided simultaneously.
63. The method of claim 62, wherein the pharmaceutical composition and the anti-inflammatory agent are provided as two different pharmaceutical compositions.
64. 63. The method of claim 62, wherein the pharmaceutical composition and the anti-inflammatory agent are provided as a single pharmaceutical composition.
65. 62. The method of claim 60 or claim 61, wherein the pharmaceutical composition is provided after the anti-inflammatory drug is provided.
66. 62. The method of claim 60 or claim 61, wherein the pharmaceutical composition is provided before the anti-inflammatory drug is provided.
67. 67. The method of any one of claims 61 to 66, wherein the anti-inflammatory drug is a non-steroidal anti-inflammatory drug selected from acetylsalicylic acid (aspirin), benzyl-2,5-diacetoxybenzoate, celecoxib, diclofenac, etodolac, etofenamate, fluindac, glycol salicylate, ibuprofen, indomethacin, ketoprofen, methyl salicylate, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, salicylic acid, salicylmide, esomeprazole, or a combination of any two or more thereof.
68. The anti-inflammatory drugs include alpha methyl dexamethasone, amcinafide, amcinafide, beclomethasone dipropionate, beclomethasone dipropionate, betamethasone and the remainder of its esters, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, beta methyl betamethasone, betamethasone, chloroprednisone, clesinolone, clobetasol valerate, clocortelone, cortisone, cortodoxone, desonide, deoxymethasone, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, difluorosone diacetate, difluprednate, fluadrenolone, flucetonide, fluclorone acetonide, flucloronide, flucortinbu 67. The method of any one of claims 61 to 66, wherein the corticosteroid is selected from the group consisting of ethyl esters, fludrocortisone, flumethasone pivalate, flunisolide, fluocinonide, fluocortolone, fluoromethalone, fluocinolone acetonide, fluperolone, fluprednidene acetate, fluprednisolone, fluradrenolon acetonide, flurandrenolone, halcinonide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydroxyltriamcinolone, medrysone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide.
69. 60. The method of any one of claims 54 to 59, further comprising administering to the subject an immunosuppressant agent.
70. 70. The method of claim 69, wherein the pharmaceutical composition and the immunosuppressant are provided simultaneously.
71. 70. The method of claim 69, wherein the pharmaceutical composition and the immunosuppressant are provided as two different pharmaceutical compositions.
72. 70. The method of claim 69, wherein the pharmaceutical composition and the immunosuppressant are provided as a single pharmaceutical composition.
73. 70. The method of claim 69, wherein the pharmaceutical composition is provided after the immunosuppressant is provided.
74. 70. The method of claim 69, wherein the pharmaceutical composition is provided before the immunosuppressant is provided.
75. 75. The method of any one of claims 69 to 74, wherein the immunosuppressant is selected from antibodies (e.g., basiliximab, daclizumab, and muromonab), anti-immunophilins (e.g., cyclosporine, tacrolimus, and sirolimus), antimetabolites (e.g., azathioprine and methotrexate), cytostatics (e.g., alkylating agents), cytotoxic antibiotics, interferons, mycophenolates, opioids, small molecule biological agents (e.g., fingolimod and myriocin), and TNF binding proteins.
76. 60. The method of any one of claims 54 to 59, further comprising administering to the subject an anti-inflammatory drug and an immunosuppressant.
77. 60. The method of any one of claims 54 to 59, further comprising administering to the subject a second pharmaceutical composition comprising an IL-12 / IL-23 inhibitor and / or an IL-17 inhibitor.
78. 78. The method of claim 77, wherein the pharmaceutical composition and the immunosuppressant are provided simultaneously.
79. 78. The method of claim 77, wherein the pharmaceutical composition and the immunosuppressant are provided as two different pharmaceutical compositions.
80. 78. The method of claim 77, wherein the pharmaceutical composition and the immunosuppressant are provided as a single pharmaceutical composition.
81. 78. The method of claim 77, wherein the pharmaceutical composition is provided after the immunosuppressant is provided.
82. 78. The method of claim 77, wherein the pharmaceutical composition is provided before the immunosuppressant is provided.
83. 75. The method of any one of claims 69 to 74, wherein the IL-17 inhibitor is selected from secukinumab, ixekizumab, bimekizumab, and brodalumab.
84. 75. The method of any one of claims 69 to 74, wherein the IL12 / IL-23 inhibitor is selected from usekinumab, risankizumab, guselkumab, and tildrakizumab.
85. A pharmaceutical composition according to any one of claims 38 to 48 for use in the treatment or prevention of inflammation.
86. 38. The chimeric protein of any one of claims 1 to 24, the isolated polynucleotide of any one of claims 25 to 34, the mmRNA of any one of claims 26 to 30, the vector of claim 35, or the host cell of claim 37 for use in the treatment or prevention of inflammation.
